CA2807097A1 - Matrix metalloproteinase inhibitors - Google Patents

Matrix metalloproteinase inhibitors Download PDF

Info

Publication number
CA2807097A1
CA2807097A1 CA2807097A CA2807097A CA2807097A1 CA 2807097 A1 CA2807097 A1 CA 2807097A1 CA 2807097 A CA2807097 A CA 2807097A CA 2807097 A CA2807097 A CA 2807097A CA 2807097 A1 CA2807097 A1 CA 2807097A1
Authority
CA
Canada
Prior art keywords
compound
oxo
phenyl
hydroxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2807097A
Other languages
French (fr)
Inventor
Manoj Kumar Khera
Jitendra Sattigeri
Viswajanani Sattigeri
Neeraj Kumar Yadav
Kewal Kumar
Abdul Rehman Abdul Rauf
Ian A. Cliffe
Pradip Kumar Bhatnagar
Abhijit Ray
Punit Srivastava
Sunanda Ghosh Dastidar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of CA2807097A1 publication Critical patent/CA2807097A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention relates to certain hydroxy propionic acid derivatives and the processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over activation of a matrix metalloproteinase using the compounds.

Description

MATRIX METALLOPROTEINASE INHIBITORS

Field of the Invention The present invention relates to certain hydroxy propionic acid derivatives and the processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by over-expression and over activation of a matrix metalloproteinase using the compounds.

Background of the Invention Metalloproteinases (MMPs) are a naturally occurring superfamily of proteinases (enzymes) found in most mammals. The superfamily is composed of at least 26 members of zinc-containing enzymes produced by many cell types and sharing structural and functional features. Based on structural and functional considerations, proteinases have been classified into different families and subfamilies (Vartak et al., J Drug Targeting, 15, p. 1-20 (2007); and Hopper, FEBS, 354, p. 1-6 (1994)), such as collagenases (MMP-1, -8 and -13), gelatinases (MMP-2, and -9), metalloelastases (MMP-12), the MT-MMPs (MMP-14, -15, -16, -17, - 24 and 25), matrilysins (MMP-7 and -26), stromelysins (MMP-3, -10 and -11) and sheddases such as TNF-converting enzymes (TACE, and ACE).

Metalloproteinases are believed to be important in physiological and disease processes that involve remodeling, such as airway diseases, embryonic development, bone formation and uterine remodeling during menstruation. One major biological function of MMPs is to catalyze the breakdown of connective tissues or extra-cellular matrix by their ability to hydrolyze various components of tissue or matrix. Apart from their role in degrading connective tissue, MMPs are involved in the activation of zymogen (pro) forms of other MMPs thereby inducing MMP activation. They are also involved in the biosynthesis of TNF-alpha which is implicated in many pathological conditions.

MMP-9, which belongs to the gelatinase family, plays a major role in chronic inflammatory disorders like COPD, asthma and rheumatoid arthritis. The concentration of MMP-9 has been reported to increase in diseases like asthma, interstitial pulmonary fibrosis (IPF), adult respiratory distress syndrome (ARDS), and in chronic obstructive pulmonary disease (COPD). Because of its proteolytic ability, MMP-9 has been implicated in tissue remodeling of the airways and lungs in chronic inflammatory diseases such as severe asthma and COPD. MMP-9 is also likely to be physiologically important because of its ability to regulate the digestion of components of the extracellular matrix as well as the activity of other proteases and cytokines. MMP-9 is secreted in neutrophils, macrophages, and osteoclasts, which are easily induced by cytokines and growth factors, and plays a role in various physiological and pathological processes.
WIMP-12, also known as macrophage elastase or metalloelastase, is expressed in activated macrophages and has been shown to be secreted from alveolar macrophages from smokers, as well as in foam cells in atherosclerotic lesions. MMP-12 knockout mouse studies have shown the development of significant emphysema, thus supporting its role in COPD. MMP-9 (gelatinase B, 92 kDa Type IV collagenase) is one member of the MMP family that is released as a proenzyme and subsequently activated via a protease cascade in vivo.

Over-expression or over-activation of an MMP, or an imbalance between an MMP
and a natural (i.e., endogenous) tissue inhibitor of a matrix metalloproteinase (TIMP) has been linked to a pathogenesis of diseases characterized by the breakdown of connective tissue or extracellular matrix.

Inhibition of the activity of one or more MMPs may be of benefit in treatment of various inflammatory, autoimmue and allergic diseases, such as, inflammation of the joint, inflammation of the GI tract, inflammation of the skin, collagen remodeling, wound healing disorders, etc.

The design and therapeutic application of MMP inhibitors has revealed that the requirement of a molecule to be an effective inhibitor of MMP class of enzymes is a functional group (e.g.. carboxylic acid, hydroxamic acid or sulphydryl) capable of chelating to the active site Zn2+ ion (Whittaker et al., Chem. Rev., 99; p.
2735-76 (1999)).

WO 2004/014310 discloses processes for the preparation of peripheral opioid antagonist compounds useful for gastrointestinal motility disorders. WO

discloses processes for preparing chromanylbenzoic acids. WO 94/20455 discloses styryl derivatives as PDE-IV inhibitors useful in the prophylaxis and treatment of diseases such as asthma, where an unwanted inflammatory response or muscular spasm is present. WO
2004/110974 discloses compounds and their physiologically functional derivatives described as inhibitors of matrix metalloproteinase enzymes. WO 2004/113279 discloses inhibitors of matrix metalloproteinase. WO 2005/026120 discloses compounds described as inhibitors of matrix metalloproteinase. U. S. Patent Application No.

discloses diflourobutyric acid compounds useful for treating diseases associated with zinc metalloprotease activity. WO 2006/090235 describes 5-phenyl-pentanoic acid derivatives described as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases. WO 2008/023336 discloses P-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors.

Research has been carried out into the identification of inhibitors that are selective, e.g., for a few of the MMP subtypes. An MMP inhibitor of improved selectivity would avoid potential side effects associated with inhibition of MMPs that are not involved in the pathogenesis of the disease being treated.

Further, use of more selective MMP inhibitors would require administration of a lower amount of the inhibitor for treatment of disease than would otherwise be required and, after administration, partitioned in vivo among multiple MMPs. Still further, the administration of a lower amount of compound would improve the margin of safety between the dose of the inhibitor required for therapeutic activity and the dose of the inhibitor at which toxicity is observed.

Many drugs exist as asymmetric three-dimensional molecules, i.e., chiral, and will therefore have several stereoisomers depending upon the number of chiral centers present.
The importance of evaluating new chemical entities having chiral centers as single isomers is to understand their effect on pharmacological and toxicological aspects.
There are often pharmacodynamic, pharmacokinetic and/or toxicological differences between enantiomers/diastereomers. Even if natural physiological mediators are achiral, based on their target environment, their receptors/enzymes may demonstrate a preference for only one optically pure enantiomer of agonists, antagonists or inhibitors. From a pharmacokinetics point of view, chirality can have an influence on drug absorption, distribution, metabolism and elimination. Pure single isomers may also offer advantages in terms of these pharmacokinetic parameters thus enabling better developability of such molecules as drug candidates. It is also known that chirality has a significant effect of the physicochemical properties and crystallinity of a chiral molecule which in turn have profound effects on the pharmacokinetics and developability of the molecule.
Besides those mentioned above, regulatory principles guide one to preferably develop single isomers as drug candidates in order to avoid any pharmacological, pharmacokinetic and toxicological problems that may arise due to interactions of an unwanted isomer with undesirable molecular targets.
In this context, synthetic strategies to produce pure single isomers offer advantages over analytical techniques of separation of isomer not only in terms of cost and efficiency but larger amounts of compound can be prepared for elaborate pharmaceutical testing.
Thus, compounds of present invention, which are single chiral isomers, have improved potency, improved pharmacokinetics and/or improved physicochemical properties as compared to racemic compounds.
The present invention is directed to overcoming problems encountered in the art.
Summary of the Invention The present invention provides some hydroxy propionic acid derivatives, which act as matrix metalloprotease inhibitors, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention.
The present invention relates to matrix metalloproteinase inhibitors useful as effective therapeutic or prophylactic agents in treatment of various inflammatory, autoimmune, and allergic diseases and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.
The present invention discloses a novel class of compounds that are dual MIYIP-9/12 inhibitors and have desirable activity profiles. The compounds of this invention have beneficial potency and/or selectivity.
Pharmaceutical compositions containing such compounds are provided together with the pharmaceutically acceptable carriers or diluents, which can be used for the treatment or prevention of inflammatory or autoimmune diseases. These pharmaceutical compositions may be administered or coadministered by a wide variety of routes including, for example, oral, topical, rectal, intranasal or by parenteral route. The composition may also be administered or co-administered in slow release dosage forms.

Although the specific enantiomers have been shown by way of examples, the racemates, diastereomers, pharmaceutically acceptable salts, and pharmaceutically acceptable solvates, having the same type of activity, are also provided.
Pharmaceutical compositions comprising such compounds, with optionally included excipients are also provided.
Therapeutically effective amounts of one or more compounds of the present invention can be used in combination with one or more other therapeutic agents, for example, other anti-inflammatory agents, beta agonists, antihypertensive agents, immunosuppressive agents and anti-infective agents.
Other objects will be set forth in accompanying description and in the part will be apparent from the description or may be learnt by the practice of the invention.
Detailed Description of The Invention In accordance with one aspect, there are provided compounds having the structure of Formula I:
OH OH
Cr. -V-W

Formula I
including racemates, enantiomers and diastereomers thereof, or a pharmaceutically acceptable salt thereof wherein, 0 can be selected from phenyl, fluorophenyl, heteroaryl or heterocyclyl;
U can be a selected from bond, -NH-, -C(=0)- , -(CH2)n-, -C(=S)-, -0-, -SO2_ or -S
- wherein n can be zero or an integer between 1 and 2;
V can be a selected from bond, -NH-, -C(=O)-, -C(=S)- or W can be a selected from bond, -NH-, -C(=0)-,(CH2)n-, -C(=S)-, -0-, -S- or 11111 can be selected from aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which can be further substituted by one or more substituent independently selected from R1 can be selected from alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-Cl-C6 alkyl, halogeno-C1-C6 alkoxy, azido, thiol, alkylthiol, -(CH2).-ORf, -C(=0)-Rf, -COORf, -NRfRq, -(CE12)n-C(=0)NRfRq, -(CH2)n-NHC(=0)-Rf, -(CH2)õ- 0-C(=0)-NRfRq, (CH2)õ NHC(=0)NRfRq,, -(CE12)n-o-C(=0)- Rf, -(CH2)n-NH-C(=0)-Rf or -(CH2)nS(=0)m-NRfRq {wherein Rf and Rq are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and alkylheterocyclyl, n is as defined earlier and m is an integer 0-2};

111 can be selected from heteroaryl or heterocyclyl.
In accordance with another aspect, there are provided compounds having the structure of Formula Ia:
OH OH
Li 0 Formula Ia including racemates, enantiomers and diastereomers thereof, or a pharmaceutically acceptable salt thereof wherein, can be selected from phenyl, fluorophenyl, heteroaryl or heterocyclyl;
L1 can be a selected from bond, -(CH2)n_, -NHCO(CH2)n_, -(CH2)nC(=0)NH-, -NHC(=0)NH-, -SO2NH-, -NHS02_, -SO2, _NHC(=0)(0)-, -0-(CE12)n-, -(CH2)n-0-, -(CH2)n0C(=0)NH-, -C(=S)NH-, -NHC(=S)- or -NHC(=S)NH- wherein n can be zero or an integer between 1 and 2;

_EID can be selected from aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which can be further substituted by one or more substituents independently selected from RI.
RI can be selected from alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-CI-C6 alkyl, halogeno-C1-C6 alkoxy, azido, thiol, alkylthiol, -(CH2)õ-ORf, -C(=0)-R6 -COORf, -NRfRq, -(CH2)õ-C(-0)NRAI, -(CH2)õ-NHC(=0)-Rf, -(CH2)n- 0-C(=0)-NRfRq, (CH2)n NHC(=0)NRfRq,, -(C112)n-0-q=0)- Rt., -(C112)q-NH-C(=0)-Rf or -(CH2)qS(---0)m-NRIRI {wherein Rf and Rq are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and alkylheterocyclyl, n is as defined earlier and m is an integer 0-2};

0 can be selected from heteroaryl or heterocyclyl.
In yet another aspect, the current invention provides a compound of Formula Ib:
- a OH OH
0 L1 I.

Formula lb including racemates, enantiomers and diastereomers thereof, or a pharmaceutically acceptable salt thereof wherein, lican be selected from mono, bi or polycyclic heteroaryl or heterocyclyl selected from the following , 1 Nk /N
I I I (R ), la I

N., ..õ....-..)--.....;,...N /

N
Il (Ri)v Tvµ

1\ 0 \ N
+NAo -Thl 1 -õ,õõ...-------// , 1'1.---0>
(R1)v \\ (R )v )--*

i j,/. .. .,......,..........,..\,(1- N....
(R1)v i I / , y ) 1 '/..---) (R )v ........, (R1 )v (Ri)v 0 N (RN )v N
i 0 H
I

-1-Nj0 INV 1 NV
)._.7/
I / J/
I
,-, N

YN7 1 N 0 R1);------Th( ( (R, )v (R )v )v HN--1( I/ ) I /

(R1)0 (R1);----Y
o'''''..----\ 1 (R1)v (R )v wherein R1 is as defined earlier and v can be zero or an integer between 1-4.

Ra can be hydrogen or fluorine;

Li and are as defined earlier.

In yet another aspect, the current invention provides a compound of Formula Ic:

OH OH

- a 1a 110 4:11 L

pill go 2-3 , Formula Ic including racemates, enantiomers and diastereomers thereof, or a pharmaceutically acceptable salt thereof, wherein, La is selected from S(0)., NHCO(CH2). and NHCO(0);

Ra, 0andli are as defined earlier.

The enantiomers, diastereomers, rotational isomers, N-oxides, polymorphs, pharmaceutically acceptable salts and pharmaceutically acceptable solvates of these compounds, prodrugs and metabolites having the same type of activity are also provided, as well as pharmaceutical compositions comprising the compounds, their metabolites, enantiomers, diastereomers, conformational isomers, N-oxides, polymorphs, solvates or pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable carrier and optionally included excipients.

In one embodiment, the invention encompasses compounds of Formula (I), which may include, but are not limited to the following, for example (25)-2- [(S)- {4- [(4-Chlorophenyl)sulfinyl] phenyl (hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 1);

(2S)-2-[(S)- {4- [(4-Chlorophenyl)sulfonyl] phenyl}(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 2);

(25)-2- [(S)- {4- [(3 ,4-Difluorophenyl)sulfinyl]phenyl (hydroxy)methyl] -4-(4-oxo-1,2,3-benzo triazin-3(41])-yl)butanoic acid (Compound No. 3);

(25)-2- [(5)- {4- [(2,3 -Dichlorophenyl)sulfinyl] phenyl}(hydroxy)methyl] -4-(4-oxo-1,2,3 -benzo triazin-3(4H)-yl)butanoic acid (Compound No. 4);

(2S)-2-[(S)- {4- [(2,4-Dimethylphenyl)sulfinyl]phenyl (hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yebutanoic acid (Compound No. 5);

(25)-2- [(5)- { 4- [(4-Fluorophenyl)sulfonyl]phenyll (hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(41/)-yl)butanoic acid (Compound No. 6);

(2S)-2-[(S)- {4-[(3 ,4 -D ifluorophenyl)sulfonyl]phenyll(hydroxy)methyl] -4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 7);

2-[{4-[(2,3-Dichlorophenyl)sulfonyl]phenyll(hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(41/)-y1)butanoic acid (Compound No. 8);
(25)-2- [(S)- {4- [(2,4 -Dimethylphenyl)sulfonyl]phenyll(hydroxy)methyl] -4 -(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 9);

(25)-2- [(5)-(4- [(4-Ethylphenyl)carbonyl]aminolphenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 10);

(25)-2- [(5)-(4- [(4-Chlorophenyl)carbonyl]aminolphenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 11);

(2S)-2- [(S)-(4- [(3 ,4 -Dichlorophenyl)carbonyl] amino }
phenyl)(hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 12);
(2S)-2- [(S)-Hydroxy(4- [(4-methoxyphenyl)carbonyl] amino } phenyl)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yObutanoic acid (Compound No. 13);
(2S)-2-[(S)-Hydroxy(4- [(3 -methoxyphenyl)c arbonyl] amino phenyl)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 14);
(2S)-2-[(S)-Hydroxy(4- [(4-methylphenyl)carbonyl ] amino } phenyl)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 15);
(2S)-2- [(S)-(4- [(4-Fluorophenyl)carbonyl ] amino } phenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 16);
(2S)-2- (S)-Hydroxy[4-({ [4-methoxy-3-(trifluoromethyl)phenyl]carbonyl }
amino) phenyl] methyl} -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 17);
(2S)-2-[(S)-Hydroxy(4- [(5-methyl-1,2-oxazol-3-y1)carbonyl] amino phenyl)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 18);
(2S)-2-[(S)-(4- [(3 -Chloro-4-fluorophenyl)carbonyl] amino phenyl) (hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 19);
(2S)-2-[(S)-Hydroxy {4- [(phenylcarbonyl)amino]phenyl } methy1]-4-(4-oxo-1,2,3-benzotriazin-3 (4H)-yl)butanoic acid (Compound No. 20);
(2S)-2-[(S)-Hydroxy(4- [(4-propylphenyl)carbonyl] amino } phenyl)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 21);
(2S)-2-[(S)-Hydroxy {4- [(phenoxycarbonyl)amino]phenyl } methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 22);
(25)-2-[(S)-Hydroxy{4-[(phenylacetyl)amino]phenyllmethyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-y1)butanoic acid (Compound No. 23);
(2S)-2-[(S)-(4-{ [(2,4-Dichlorophenyl)carbonyl]amino phenyl)(hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 24);
(2S)-2-[(S)-Hydroxy(4- [(2-methylphenyl)carbonyl] amino phenyl)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 25);
(2S)-2-[(S)-(4- [(2-Fluorophenyl)carbonyl] amino phenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 26);
(2S)-2-[(S)-(4-{ [(3-Chlorophenyl)carbonyl]amino phenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 27);
(2S)-2- [(S)-Hydroxy(4- [(3 -methylphenyl)c arbonyl] amino } phenyl)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 28);
(2S)-2-[(S)-(4- [(3 -F luorophenyl)carb onyl] amino phenyl)(hydroxy)methyl] -oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 29);
(2S)-2-[(S)-(4- [(2,6-Dimethoxyphenyl)c arbonyl] amino} phenyl)(hydroxy) methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 30);

(25)-2- [(5)- {4- [(Cyc lop entylcarbonyl)amino] phenyll(hydroxy)methyl] -4-(4-oxo-1,2,3 -benzo triazin-3(4H)-yl)butanoic acid (Compound No. 31);
(25)-2- [(5)-Hydroxy(4- [(2,4,5-trifluoro-3-methoxyphenyl)carbonyl]amino}
phenyl) methyl] -4-(4-oxo-1,2,3-b enzotriazin-3(4H)-yl)butanoic acid (Compound No. 32);
(25)-2-[(5)-Hydroxy(4-{ [(2,3,4-trifluorophenyl)carbonyl] amino}
phenyl)methyl] -4-(4-oxo-1,2,3 -b enzotriazin-3(4H)-yl)butanoic acid (Compound No. 33);
(25)-2- {(S)-Hydroxy[4-({ [2-(trilluoromethyl)phenyl] carbonyllamino)phenyl]
methyl} -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 34);
(25)-2- [(5)-(4- [(3,5-Dimethoxyphenyl)carbonyl]aminolphenyl)(hydroxy) methyl] -4-(4-oxo-1,2,3-b enzotriazin-3(4H)-yl)butanoic acid (Compound No.
35);
(2S)-2-[(S)-(4- [(2,3 -Difluorophenyl)c arbony] ] amino phenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3 -benzotriazin-3(4H)-yl)butanoic acid (Compound No. 36);
(25)-2-[(5)-(4-{ [(3,5-Dichlorophenyl)carbony] ] amino phenyl)(hydroxy)methyl]

(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 37);
(2S)-2-[(S)-(4-{ [(2,4-Difluorophenyl)carb onyl] amino}
phenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3 -benzotriazin-3(4H)-yl)butanoic acid (Compound No. 38);
(25)-2-[(5)-(4-{ [(2,6-Difluorophenyl)c arbonyl ] amino }phenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3 -benzotriazin-3(4H)-yl)butanoic acid (Compound No. 39);
(25)-2- [(5)-Hydroxy(4- [(2-methoxyphenyl)carbonyl] amino phenyl)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 40);
(2S)-2-[(S)- {4- [(Cyclohexylcarbonyl)amino]phenyll(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 41);
(25)-2- [(5)-(4- [(4-Ethoxyphenyl)carbony] ] aminolphenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 42);
(25)-2-[(5)-(4-{ [(3,4-Difluorophenyl)carbonyl ] amino 1 phenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 43);
(25)-2- (5)-Hydroxy[4-({ [4-(trifluoromethoxy)pheny]]carbonyllamino)phenyl]
methyl} -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 44);
(25)-2-{(5)-Hydroxy[4-({ [3-(trifluoromethyl)phenyl]carbonyllamino)phenyl ] methyl 1 -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 45);
(2S)-2-[(S)44-({ [2-Fluoro-4-(trifluoromethyl)phenyl] carbonyl) amino) phenyl ](hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 46);
(25)-2- [(5)-(4- [(3-Chloro-2,6-difluorophenyl)carbonyl] amino 1 phenyl)(hydroxy) methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 47);
(25)-2- (5)-Hydroxy[4-({ [4-(trifluoromethyl)phenyl]carbonyllamino)phenyl]
methyl} -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 48);
(2S)-2-[(S)-(4- [(2,5-Difluorophenyl)carbony] ] amino }
phenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 49);

(2S)-2-[(S)-(4-{[(2,3-Difluoro-4-methylphenyl)carbonyl]aminolphenyl)(hydroxy) methy1]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 50);

(2S)-2-[(S)- [4-( [4-Fluoro-3-(trifluoromethyl)phenyl] carbonyl} amino)phenyl]

(hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yObutanoic acid (Compound No. 51);

(2S)-2-[(S)-{4-[(Cyclopropylcarbonyl)amino]phenyll(hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yObutanoic acid (Compound No. 52);

(2S)-2-[(S)-(4-{[(2-Ethylphenyl)carbonyl]aminolphenyl)(hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 53);

(2S)-2-[(S)-Hydroxy(4-{[(4-methoxyphenyl)acetyl]aminolphenyl)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(41/)-yObutanoic acid (Compound No. 54);

(2S)-2-[(S)-{4-[(Cyclobutylcarbonyl)amino]phenyll(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 55);

(2S)-2- {(S)-Hydroxy[4-(4-methoxyphenoxy)phenyl]methyll -4-(4-oxo-1,2,3 -benzotriazin-3(411)-yebutanoic acid (Compound No. 56);

(2S)-2-[(S)-[4-(3-Chloro-4-fluorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yebutanoic acid (Compound No. 57);

(2S)-2-[(S)-[4-(4-Chloro-3-methylphenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound no. 58);

(2S)-2-[(S)-[4-(4-Chloro-2-fluorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 59);

(2S)-2-[(S)-[4-(4-Fluorophenoxy)pheny]](hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 60);

(2S)-2-[(S)-[4-(3,4-Difluorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(41/)-yebutanoic acid (Compound No. 61);

(2S)-2-[(S)-[4-(2-Chlorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(41/)-yl)butanoic acid(Compound No. 62);

(2S)-2-[(S)-[4-(3-Chlorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 63);

(25)-2-[(5)-[4-(2,6-Difluorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 64);

(2S)-2-[(S)-[4-(2,5-Dichlorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(41/)-yebutanoic acid (Compound No. 65);

(2S)-2-[(S)-[4-(2-Chloro-4-fluorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 66);

(2S)-2- { (S)-Hydroxy[4-(3-methoxyphenoxy)phenyl]methy11-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 67);

(2S)-2-[(S)-[4-(2-Chloro-4-methoxyphenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 68);

(25)-2-[(5)-[4-(2,4-Difluorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(41/)-yl)butanoic acid (Compound No. 69);
(25)-2-[(S)-[3-Fluoro-4-(4-methylphenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 70);
(25)-2-[(5)-[3-Fluoro-4-(3-methylphenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 71);
(25)-2-[(5)-[4-(3,4-Dimethylphenoxy)-3-fluorophenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-berizo triazin-3(411)-yl)butanoic acid (Compound No. 72);
(25)-2-[(5)-[4-(3,4-Dichlorophenoxy)-3-fluorophenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 73);
(25)-2-[(S)44-(4-tert-Butylphenoxy)-3-fluorophenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 74);
(25)-2-[(5)-[3-Fluoro-4-(4-methoxyphenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(41/)-yl)butanoic acid (Compound No. 75);
including racemates, enantiomers and diastereomers thereof, or a pharmaceutically acceptable salt thereof.

In another aspect, provided herein are pharmaceutical compositions comprising therapeutically effective amounts of one or more compounds described herein together with one or more pharmaceutically acceptable carriers, excipients or diluents.

In another aspect, provided herein are compounds according to Formula I/Ia/Ib/Ic for use in medicine.

In another aspect, provided herein are compounds according to Formula I/Ia/Ib/Ic for use in treating or preventing various inflammatory and allergic diseases comprising administering to a mammal in need thereof.

In another aspect, provided herein are compounds according to Formula I/Ia/Ib/Ic wherein various inflammatory and allergic diseases are asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation associated with restenosis and ischemic heart failure, stroke, renal disease or tumour metastasis.

In yet another aspect, the present invention relates to the therapeutically effective dose of a compound of Formula I/Ia/Ib/Ic in combination with one or more of other therapeutic agents used for treating various inflammatory and allergic diseases. Examples of such therapeutic agents include, but are not limited to:

1) Anti-inflammatory agents, experimental or commercial (i) such as nonsteroidal anti-inflammatory agents piroxicam, diclofenac, propionic acids, fenamates, pyrazolones, salicylates, phosphodiesterase inhibitors including PDE-4 inhibitors, p38 MAP Kinase/Cathepsin inhibitors, CCR-3 antagonists, iNOS
inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists, cell adhesion inhibitors (specially ICAM), adenosine 2a agonists, (ii) leukotrienes LTC4/LTD4/LTE4/LTB4-Inhibitors, 5-lipoxygenase inhibitors and PAF-receptor antagonists, (iii) Cox-2 inhibitors (iv) other MMP inhibitors, (v) interleukin-I inhibitors, (vi) corticosteroids such as alclometasone, amcinonide, amelometasone, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, cloticasone, cyclomethasone, deflazacort, deprodone, dexbudesonide, diflorasone, difluprednate, fluticasone, halometasone, haloperedone, hydrocortisone, methylprednisolone, mometasone, prednicarbate, prednisolone, rimexolone, tixocortol, triamcinolone, ulobetasol, rofleponide, GW 215864, KSR 592, ST-126, dexamethasone and pharmaceutically acceptable salts, solvates thereof.
Preferred corticosteroids include, for example, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, and dexamethasone;

2) Beta-agonists, experimental or commercial (i) suitable 132-agonists include, for example, one or more of albuterol, salbutamol, biltolterol, pirbuterol, levosalbutamol, tulobuterol, terbutaline, bambuterol, metaproterenol, fenoterol, salmeterol, carmoterol, arformoterol, formoterol, and their pharmaceutically acceptable salts or solvates thereof one or more 132- agonists may be chosen from those in the art or subsequently discovered. (ii) The 132-agonists may include one or more compounds described in, for example, U.S. Patent Nos.
3,705,233; 3,644,353; 3,642,896; 3,700,681; 4,579,985; 3,994,974; 3,937,838;
4,419,364; 5,126,375; 5,243,076; 4,992,474; and 4,011,258;

3) antihypertensive agents, (i) ACE inhibitors, e.g., enalapril, lisinopril, valsartan, telmisartan and quinapril, (ii) angiotensin II receptor antagonists and agonists, e.g., losartan, candesartan, irbesartan, valsartan, and eprosartan, (iii)13-blockers, and (iv) calcium channel blockers;

4) immunosuppressive agents, for example, cyclosporine, azathioprine and methotrexate, anti-inflammatory corticosteroids; and 5) anti-infective agents (e.g., antibiotics, antivirals).
Definitions The following definitions apply to terms, as used herein:
The term "alkyl" refers to a straight or branched fully saturated hydrocarbon chain which is optionally substituted by one or more halo atom, and which has 1 to 20 carbon atoms unless otherwise specified. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-hexyl, n-decyl, n-tetradecyl, trifluoromethyl, chloroethyl, and the like.
The term "alkenyl", unless otherwise specified, refers to a branched or unbranched unsaturated hydrocarbon group containing at least one double bond with cis or trans geometry and preferably having 2 to 20 carbon atoms. Examples of alkenyl group include ethenyl, 2-propenyl and isopropenyl.
The term "cycloalkyl" refers to a non aromatic cyclic group having 3 to 20 ring carbon atoms and form one to three rings and may optionally contain one or more olefinic bonds. Polycyclic ring systems may be a spiro, fused or bridged arrangement.
Cycloalkyl groups include, by way of example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, adamantyl, bicyclo [2.2 .1]heptanyl, bicyclo [2.2.2] octane, tricycle [3.3.1 .]] decane, and the like.
The term "aryl" refers to an aromatic system having from 6 to 14 carbon atoms and up to three rings which may be fused or directly joined. Representative examples of such aryl group include, but are not limited to, phenyl, biphenyl, naphthyl, phenanthrene, anthracenyl, azulenyl, and indanyl. Aryl group may also comprise one or more rings which are not fully aromatic and examples of such system are indane, indene, 2, 3 dihydrobenzofuran and 1,2,3,4-tetrahydronaphthalene The term "heteroaryl" refers to an aromatic system having from 5 to 14 membered carbon atoms and up to three rings, which may be fused or directly joined, and containing from one to eight heteroatoms selected from N, 0 and S. Examples of heteroaryl groups are pyridinyl, quinolinyl, oxazolyl, imidazolyl, pyrrolyl, thiophenyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, thiazolyl, oxadiazolyl, benzoimidazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, thienyl, isoxazolyl, triazinyl, fiiranyl, benzofuranyl, indolyl, benzothiazolyl, benzoxazolyl, and the like.
The term "heterocyclyl" refers to a non-aromatic monocyclic or polycyclic ring system, which may be fused spiro or bridged, having 3 to 12 ring atoms and up to eight heteroatoms selected from N, 0 and S. Examples of heterocyclyl ring systems include piperidine, morpholine, piperazine, isoquinoline, oxazolidine, tetrahydrofuran, dihydrofuran, dihydropyridine, dihydroisoxazole, dihydrobenzofuran, azabicyclohexane, dihydroindole, tetrahydroquinoline, pyrrolidine, azepine, azetidine, aziridine, tetrahydropyridine, benzthiazine, benzoxazinyl, isoindoline, azabicycle[3.1.0]hexyl, phenoxazine, tetrahydropyran, 1,4-dioxane, and the like.
The terms "cycloalkylalkyl","arylalkyl","heteroarylalkyl","heterocyclylalkyl", refers respectively, to cycloalkyl, aryl, heteroaryl or heterocyclyl group linked to the remainder of the molecule via an alkyl group.
The term "amino" refers to -NH2.
The term "alkoxy" denotes the group 0-alkyl, wherein alkyl is the same as defined above.
The term "halogen" or "halo" refers to fluorine, chlorine, bromine or iodine.
The term "halogeno-Ci-C6alkyl" refers to Ci-C6alkyl of which one or more hydrogen(s) is/are replaced by halogen.
The term "halogeno C1-C6 alkoxy" refers to as halogen atom bonded to C1-C6 alkoxy group. Examples of such groups include trifluoromethoxy, trichloromethoxy, difluoromethoxy, fluoromethoxy, 2,2,2-trifluoroethoxy, 2-bromoethoxy etc.
The term "hydroxyl" or "hydroxy" refers to ¨OH.
The term "thior' refers to the group ¨SH.
The term "alkylthiol" refers to a thiol group when hydrogen is replaced by alkyl, for example, methylthio, ethylthio, propylthio, t-butylthio, cyclopropylthio, and the like.
The term "cyano" refers to as CI\T.
The term "azido" refers to as N=N=N.

The term "leaving group" refers to groups that exhibit or potentially exhibit the properties of being labile under the synthetic conditions and also of being readily separated from synthetic products under defined conditions. Examples of leaving groups include, but are not limited to, halogen (e.g., F, Cl, Br, I), triflates, tosylate, mesylates, alkoxy, thioalkoxy, or hydroxy radicals, and the like.

The term "protecting groups" refers to moieties that prevent chemical reaction at a location of a molecule intended to be left unaffected during chemical modification of such molecule. Unless otherwise specified, protecting groups may be used on groups, such as hydroxy, amino, or carboxy. Examples of protecting groups are found in T.W.
Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis", 2nd Ed., John Wiley and Sons, New York, N.Y. The species of the carboxylic protecting groups, amino protecting groups or hydroxy protecting groups employed are not critical, as long as the derivatised moieties/moiety are/is stable to conditions of subsequent reactions and can be removed without disrupting the remainder of the molecule.

Compounds described herein can contain one or more asymmetric carbon atoms and thus occur as diastereomers. These compounds can also exist as conformers/rotamers.
All such isomeric forms of these compounds are included herein. Each stereogenic carbon may be of the R or S configuration. Although the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral center or mixtures thereof are envisioned.

The term "pharmaceutically acceptable salts" forming part of this invention includes the salts of carboxylic acid moiety, which may be prepared by reacting the compound with appropriate base to provide corresponding base addition salts.
Examples of such bases are alkali metal hydroxide including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides such as magnesium hydroxide and calcium hydroxide. Further, the salts of organic bases such as lysine, arginine, guanidine, ethanolamine, choline and the like; inorganic bases e.g., ammonium or substituted ammonium salts are also included. Wherever appropriate, compounds of the present invention may also form the acid addition salts by treating the said compounds with pharmaceutically acceptable organic and inorganic acids, e.g., hydrohalides such as hydrochloride, hydrobromide, hydroiodide; other mineral acids and their corresponding salts such as sulphate, nitrate, phosphate, etc.; and alkyl and mono-arylsulphonates, such as ethane sulphonate, toluene sulphonate and benzene sulphonate; and other organic acids and their corresponding salts such as acetate, tartarate, maleate, succinate, citrate, etc. The salt forms differ from the compound described herein in certain physical properties such as solubility, but the salts are otherwise equivalent for the purpose of this invention.

The term "pharmaceutically acceptable solvates" refers to solvates with water (i.e., hydrates) or pharmaceutically acceptable solvents, for example, solvates with ethanol, and the like. Such solvates are also encompassed within the scope of the disclosure.
Furthermore, some of the crystalline forms for compounds described herein may exist as polymorphs and as such are intended to be included in the scope of the disclosure.

The term "polymorphs" includes all crystalline forms as well as amorphous forms for compounds described herein and as such are included in the present invention.

The term "pharmaceutically acceptable carriers" is intended to include non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.

The term "pharmaceutically acceptable" means approved by the regulatory agency of the federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.

Examples of inflammatory conditions and autoimmune disorders in which the compounds of the invention have potentially beneficial effects in treatment methods may include, but are not limited to diseases of the respiratory tract such as asthma (including allergen-induced asthmatic reactions), cystic fibrosis, bronchitis (including chronic bronchitis), chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), chronic pulmonary inflammation, rhinitis and upper respiratory tract inflammatory disorders (URID), ventilator induced lung injury, silicosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, bronchopulmonary dysplasia, arthritis, e.g., rheumatoid arthritis, osteoarthritis, infectious arthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, Reiter's syndrome, gouty arthritis and prosthetic joint failure, gout, acute synovitis, spondylitis and non-articular inflammatory conditions, e.g., herniated/ruptured/prolapsed intervertebral disk syndrome, bursitis, tendonitis, tenosynovitic, fibromyalgic syndrome and other inflammatory conditions associated with ligamentous sprain and regional musculo skeletal strain, inflammatory disorders of the gastrointestinal tract, e.g., ulcerative colitis, diverticulitis, Crohn's disease, inflammatory bowel diseases, irritable bowel syndrome and gastritis, multiple sclerosis, systemic lupus erythematosus, scleroderma, autoimmune exocrinopathy, autoimmune encephalomyelitis, diabetes, tumor angiogenesis and metastasis, cancer including carcinoma of the breast, colon, rectum, lung, kidney, ovary, stomach, uterus, pancreas, liver, oral, laryngeal and prostate, melanoma, acute and chronic leukemia, periodontal disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy, muscle degeneration, inguinal hernia, retinal degeneration, diabetic retinopathy, macular degeneration, inguinal hernia, ocular inflammation, bone resorption diseases, osteoporosis, osteopetrosis, graft vs. host reaction, allograft rejections, sepsis, endotoxemia, toxic shock syndrome, tuberculosis, usual interstitial and cryptogenic organizing pneumonia, bacterial meningitis, systemic cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), malaria, leprosy, leishmaniasis, Lyme disease, glomerulonephritis, glomerulosclerosis, renal fibrosis, liver fibrosis, pancrealitis, hepatitis, endometriosis, pain, e.g., that associated with inflammation and/or trauma, inflammatory diseases of the skin, e.g., dermatitis, dermatosis, skin ulcers, psoriasis, eczema, systemic vasculitis, vascular dementia, thrombosis, atherosclerosis, restenosis, reperfusion injury, plaque calcification, myocarditis, aneurysm, stroke, pulmonary hypertension, left ventricular remodeling and heart failure. It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established conditions.
Compounds disclosed herein may be prepared, for example, by techniques well known in the organic synthesis and familiar to a practitioner ordinarily skilled in art of this invention. In addition, the processes described herein may enable the synthesis of the compounds of the present invention. However, these may not be the only means by which the compounds described in the invention may be synthesized. Further, the various synthetic steps described herein may be performed in alternate sequences in order to furnish the desired compounds.
The compounds of the said invention can be prepared following any of the below Schemes.

The compounds of Formulae VII, VIII and IX can be prepared by following Scheme I.

Scheme I

XH

(Rk), = ,.
(IRK)z X + 410 Formula II Formula III Formula IV
Formula V K s.

(Rk)z e Path A (when X is S) Rxõ
HO
LwL(Rk)z Formula VII Formula VI

Path B (when X is 0) 0 HO 0 (ROz 0 HO =

HO HO
(Roz Formula VIII Formula IX

Accordingly, the compound of Formula II (wherein is as defined earlier, X is 0 or S and Rk is H, halo, alkyl, alkoxy, cyano, halogeno-C1-C6 alkyl or halogeno-C1-C6 alkoxy and z is 0-4) can react with a compound of Formula III to give a compound of Formula IV, which then reacts with a compound of Formula V (wherein is as defined earlier, L and W are 0 or S respectively and Rx is alkyl, aryl or aralkyl ) to give a compound of Formula VI.

Path A (When X is S): The compound of Formula VI undergoes hydrolysis to give a compound of Formula VII, which then further undergoes oxidation to give a compound of Formula VIII.

Path B (When X is 0): The compound of Formula VI undergoes hydrolysis to give a compound of Formula IX.

The reaction of a compound of Formula II with a compound of Formula III to give a compound of Formula IV can be carried out in the presence of a base, for example, potassium carbonate, cesium carbonate, sodium acetate or potassium acetate in a solvent, for example, dimethylformamide, acetonitrile, toluene, tetrahydrofuran, acetone, dioxane, or mixture(s) thereof.

The asymmetric aldol addition of a compound of Formula IV with a compound of Formula V to give a compound of Formula VI can be carried out by generating the enolates with titanium tetrachloride, dibutyl boron triflate, dialkyl boron chloride or tin(II) triflate, in the presence of a base, for example, tetramethylethylenediamine, diisopropylethylamine, tributylamine, N-ethylpiperidine, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicyclo[5.4.0]undec-7-ene, tetramethylpropylenediamine or (-) sparteine, in a solvent, for example, dichloromethane or diethyl ether.

Hydrolysis of a compound of Formula VI (Path A, when X is S) to give a compound of Formula VII can be carried out with hydrogen peroxide and lithium hydroxide, in the presence of a solvent, for example, tetrahydrofuran, water, or mixture(s) thereof.

Oxidation of a compound of Formula VII to give a compound of Formula VIII can be carried out with an oxidizing agent, for example, meta chloro perbenzoic acid, oxone or hydrogen peroxide, in a solvent, for example, chloroform, dichoromethane, methanol, water, tetrachloromethane, or mixture(s) thereof.

Hydrolysis of a compound of Formula VI (Path B, when X is 0) to give a compound of Formula IX can be carried out in a similar way as the hydrolysis of compound of Formula VI to give a compound of Formula VII.

The compound of Formula XII can be prepared by following Scheme II.

Scheme II
Lz N G 40 OH 0 G1 OH 0 Rx Formula X
0 Rr..c.zw Formula V Formula XI Formula XII

Accordingly, the compound of Formula V (wherein 0, L, W and Rx are as defined earlier) undergoes aldol addition with a compound of Formula X
(wherein G can be nitro or C(0)0-benzyl) to give a compound of Formula XI, which then can be reduced to give a compound of Formula XII (wherein G1 can be amino or COOH).
Aldol addition of a compound of Formula X to a compound of Formula V to give a compound of Formula XI can be carried out in a similar way as the aldol addition of a compound of Formula IV with a compound of Formula V to give a compound of Formula VI.
Reduction of a compound of Formula XI to give a compound of Formula XII can be carried out with one or more reducing agents, for example, palladium-carbon/hydrogen, Raney nickel/hydrogen, platinum/hydrogen or mixture thereof in a solvent, for example, tetrahydrofuran, methanol, ethanol, propanol, isopropanol, or mixtures thereof The compound of Formula XV and XVIII can be prepared by following Scheme Scheme III
= OR

= OH

(ROz 0 -i---X /
Formula XVI Ft L
L

N--- Path D
.-1-3-\ Rxtl""W

0 Rki""'W
(Rk)z4111) Formula XII (when G1 is NH2) Formula XVII

Path C (Fik)z 0 Ni Formula xiii 0 i . OH
. OH

HN

/
NH¨
Rj\i,"
L

(7) 0 N--OH

0Rxc,w 1---\j 111) (Rk), (Rk)z Formula XIV
Formula XVIII

/

aot OH

NH¨

C<1 0 OH

(Rk)z II

Formula xv Accordingly, the compound of Formula XII (when G1 is amino) can react through two pathways.

Path C: Compound of Formula XII couples with a compound of Formula XIII
(wherein Rk and z are as defined earlier) to give a compound of Formula XIV, which then undergoes hydrolysis to give a compound of Formula XV.

Path D: Compound of Formula XII couples with a compound of Formula XVI
(wherein X

is a leaving group for example halogen and R; is -(cH2)0_1-03-, -c(o)o-, -SO2_, and Rk is as defined earlier) to give a compound of Formula XVII, which then undergo hydrolysis to give a compound of Formula XVIII.

The coupling of a compound of Formula XII with a compound of Formula XIII to give a compound of Formula XIV (Path C) can be carried out with a suitable base, for example, potassium carbonate; sodium carbonate, triethylamine, diisopropylethyl amine, etc. in the presence of solvents like acetonitrile, dimethylformamide, toluene, tetrahydrofuran, acetone or dioxane, etc.

Hydrolysis of compound of Formula XIV to give a compound of Formula XV can be carried out in a similar way as the hydrolysis of compound of Formula VI to give a compound of Formula VII.

The coupling of compound of Formula XII with a compound of Formula XVI to give a compound of Formula XVII (Path D) can be carried out with a base, for example, triethylamine (TEA), N-methyl-morpholine (NMM), N,N-dimethylaminopyridine (DMAP) or N,N-diisopropylethylamine (DIPEA) in a solvent, for example, dichloromethane, tetrahydrofuran, dimethylformamide, dioxane, acetonitrile or acetone.

Hydrolysis of compound of Formula XVII to give a compound of Formula XVIII

can be carried out in a similar way as the hydrolysis of compound of Formula VI to give a compound of Formula VII.

The compound of Formula XXI can be synthesized by following Scheme IV.

Scheme IV
HO OH 0 4.0 OH
OH
0 0 L Formula XIXHN 0 HN

Rr.cw Rx,".
(R,), (R k), Formula XII (when G1 is COON) Formula XX
Formula XXI

Accordingly, the compound of Formula XII (when G1 is COOH) can couple with a compound of Formula XIX to give a compound of Formula XX, which then undergoes hydrolysis to give a compound of Formula XXI.

The coupling of compound of Formula XII with a compound of Formula XIX to give a compound of Formula XX can be carried out in the presence of a coupling agent 1-ethyl-3 -(3 -dimethylaminopropyl) carbodiimide (EDCI) or NAT-dicyclohexylcarbodiimide (DCC) and optionally activating catalyst HOBT and an organic base dimethylaminopyridine, N-methylmorpholine or diisopropylethylamine, in an organic solvent, for example, dichloromethane, dichloroethane, chloroform and carbon tetrachloride. Alternatively, XII can also be activated by converting to the corresponding acid chloride (using thionyl chloride, oxalyl chloride, etc.) or the anhydride (pivaloyl chloride, etc.) and coupled with the corresponding anilines.
Hydrolysis of compound of Formula XX to give a compound of Formula XXI can be carried out in a similar way as the hydrolysis of compound of Formula VI to give a compound of Formula VII.
In the above schemes, where specific reagents, for example, bases, acids, solvents, condensing agents, hydrolyzing agents, catalysts etc., as mentioned, is to be understood that other reagents, e.g., other acids, bases, solvents, condensing agents, reducing agents, deprotecting agents, hydrolyzing agents, catalysts, etc., known to one of ordinary skill in the art may be used. Similarly, reaction temperatures and durations may be adjusted according to the desired needs without undue experimentation and well within the abilities of one of ordinary skill in the art.
Table 1 lists the type of compounds synthesized by using the synthetic procedure as demonstrated in Schemes I-IV.

z--z z=z z...,z z/

0 1-z/ 1- . I-I

o o 0 Z Z Z

C..) 1.4 . I .

\ , >, 0-0 1111 u. 41 0 c?

N *

n lik I

41) cl ci czt 0, o = cf3 en 6, W., ¨_i z¨z i_z/ ¨ = kz=z410 z=z co 0 o 0 I I

CA CA CA

I I I

co o¨i 0.) ei _a czt 4 ci il el eri z-z z-z z=z z=z /
/

-z /z_z 40 . 0 1 _l_z 4.0 4z 4.: 4 40 =

, z z z z z z -.;
R
(....) .
(....) .
(....) .
(....) .
(....) .
\_,..
,,,--,,--=
\õ_ u_ >4.,.
-, O

ci ee) 'Tr kr) -rp vo 'Tr N
'Tr _ z=z z¨z z¨z ,z/z=z /
/
z¨z z_z ¨1-z 1-z/ ¨
¨1-z 4./
41 --' . .¨ . .4i¨'-zi = .

, .
.
........
.
..
.

7_4 c-?:-D
c/ID
v) .
c/D
.
v) .
v) .
_ õ
>õ. .
-,,..õ/
...,,....

5 = 0--ii ft II = 5 40 co _ ci -71.
kr;
vo N
oo cr, z=z z=z z=z /z_z . -1-z/ AL\ = _i-z =-1-z/
=

ID. 0 0 0 0 II-.
o 0 Z Z Z Z
Z Z

U U U U
U
-14 L? . . .
.

u_ .,,a,õ. , = .,:,'' i' * 40 u_ '' \
\ .,,,`'.

..././.=Pt =
LL
.
LL E

.--1 el m 7r kr) kr) kr) kr) s i-z= s z/z=z= _i =-1-z/ =-1-z/ z/ z-z z=z z-z z-z o --0 0 o o == - . o Z Z Z Z
Z Z
7.4 U U U U U U
. . . .
. .

/
/ /
=sõ, >,-. / < .

=

=

.--1 t z=z zz=z= 1-z/ z_z z-z 0 _i-z o = 1.7=z =

0 -z * *
0 0 0 :

_ Z

,N Z

,-, . cl? d? d? d?

// /

- -k,n vo h oo c::

cA Zin. k,n k,n k,n kin k,n z-z z=z z-z -z --i-z/ -. ii=zAL\ 1.z/z=z= _* 4z/z_* ---1-z/
_i-z/

111 o 0 W- o 0 0 o *

.

Z Z Z Z Z

c...) c...) c...) ;4 CI) I c-i) . . cl) .Z\ \

= .),..., / = 5 . 9 d, s cc ,, el z-z i. z/z=z _i_z/ - z-z -z i z/ z-z -z -i-z/ -1-z/z- z-IC 0 = 0 = o =o 0 = 0 .

!

. .

- d? 4' _ (4) (:' '::?' .

I

it 4 , = / ,,,, .õõ. , =
m , O

4 ,-1 el en ,er lin rfj .tz .tz .tz .tz .tz _ z=z z=z z=z /z=z z-z -1-z/ z --z 0 .4, = 111-z . . .0 0 0 z z 0 z z z z !c...) 0 0 c...) c...) c...) ¨.4 R . c¨..) . c¨i) .

,¨,--- ,¨,---\

i = 40 411 m c.) = 5 (7) 40 104 ,--- _ O

4 en ,er lin .tz N
.cel el el el el el z¨z =z z=z z¨z z¨z-z -/

_i_zi i 41 41 - - , 7-4 . l'' d?
d.)1 d?
(2? (2?

,.,..,./,, /

/
/

4i 4.

i o m , \
o o o o 4:3 - 4;) t=-=
oo cl.. cz ,-1 t=-= t=-=

z-z z-z z-z z-z _ 1-z/ -i-z /
1-z/ 1-zi -z-z o o / =z-z = =

=

=

.= ,-,-c...) c...) c...) c...) c...) . , c-i) /

l' rIL

\

m A 110 LL

0 \

i f IL

O

z.
QC
cz ,-1 el en el en en en en ci . el -- 1 f z/z=z z-z z-z 7-z . * -1- z/
z 0 = 1_ *
. *

,-. 104 C1) d?
C1) C1) :
=

-,.._ / ,-,.,, ./t, / /
-.--. .õ.., . 2 = 0 Cop o f x O

el en 7r in ci N N
N N

z-z z-z z-z z-z 4z/z=z --1-z/
/ --1-z/ -= -1-z = = *

II 0 = 0 I II
, Z z z z c...) c...) "a ,-.) L?
. Li) Li.

Li.

., Li.
Li_ 6 '=
/ =
. =
c, u_ . ,, a.

m 4 It vo s oo w3 79)1. en en en en The compounds, described herein, may be administered to an animal for treatment orally, topically, rectally, internasally or by parenteral route.
Pharmaceutical compositions disclosed herein comprise pharmaceutically effective amounts of compounds described herein formulated together with one or more pharmaceutically acceptable carriers, excipients or diluents.

Solid form preparations for oral administration include capsules, tablets, pills, powder, granules, lozenges, troches, and cachets. For solid form preparations, active compounds can be mixed with one or more inert, pharmaceutically acceptable excipients or carriers, for example, sodium citrate, dicalcium phosphate and/or fillers or extenders (for example, starches, lactose, sucrose, glucose, mannitol, silicic acid, or mixtures thereof); binders, for example, carboxymethylcellulose, alginates, gelatins, polyvinylpyrrolidinone, sucrose, acacia or mixtures thereof; disintegrating agents, for example, agar-agar, calcium carbonate, potato starch, alginic acid, certain silicates, sodium carbonate, or mixtures thereof; absorption acceletors, for example, quaternary ammonium compounds; wetting agents, for example, cetyl alcohol, glycerol mono stearate or mixtures thereof; adsorbants, for example, Kaolin;
lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethyleneglycol, sodium lauaryl sulfate, or mixtures thereof Capsules, tablets or pills may also comprise buffering agents.

Tablets, capsules, pills or granules can be prepared using one or more coatings or shells to modulate the release of active ingredients, for example, enteric coatings or other coatings known to one of ordinary skill in the art.

Liquid form preparations for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or elixirs. In such liquid form preparations, active compounds can be mixed with water or one or more non-toxic solvents, solubilizing agents or emulsifiers, for example, water, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, for example, cottonseed, groundnut, corn, germ, olive, castor and sesame oil, glycerol, fatty acid esters of sorbitan or mixtures thereof Oral compositions can also include one or more adjuvants, for example, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, or mixtures thereof Injectable preparations, for example, sterile injections, and aqueous suspensions may be formulated according to methods known to one of ordinary skill in the art, and in particular, using one or more suitable dispersing or wetting and suspending agents.
Acceptable vehicles and solvents that may be employed include one or more of water, Ringer's solution, isotonic sodium chloride, or mixtures thereof Suppositories for rectal administration of the compound of this invention can be prepared by mixing the drug with suitable nonirritating excipients, such as cocoa butter and polyethylene glycols, which are solid at ordinary temperatures but liquid at body temperature and which therefore melt in the rectum and release the drug.
Dosage forms for topical or transdermal administration of a compound of the present invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. Active compounds can be admixed under sterile condition with one or more pharmaceutically acceptable carriers and optionally any preservatives or buffers as may be required. Ophthalmic formulations, eardrops, eye ointments, powders and solutions are also encompassed within the scope of this invention.
Pharmaceutical preparations may be in unit dosage form. In unit dosage form, the preparations can be subdivided into unit doses containing appropriate quantities of active components. Unit dosage forms can be packed preparations containing discrete capsules, powders, in vials or ampoules, ointments, capsules, sachets, tablets, gels, creams or any combination and number of such packed forms.

EXPERIMENTAL PROCEDURES
Various solvents, for example, dimethylformamide, benzene, tetrahydrofuran, etc., were dried using various drying reagents according to procedure as described in the literature.
Synthesis of starting materials:
Synthesis of 3-[4-((45)-4-benzy1-2-oxo-1,3-thiazolidin-3-y1)-4-oxobuty1]-3H-benzo[d][1,2,3] triazin-4-one Synthesis of the title compound was carried out according to reference procedure described in WO 2008/023336, p. 54-55.

Synthetic procedures for Scheme I (Path A) Example I: Synthesis ofi2S)-2-I(8)-{4-114-ChlorophenyljsulfonylJphenylt (hydroxy)methy11-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 2) Step 1: Synthesis of 4-[(4-chlorophenyl)sulfanyl]benzaldehyde To a solution of 4-chlorothiophenol (1.0 g, 0.0069 mol) in dimethylformamide (5m1), potassium carbonate (2.8 g, 0.0207 mol) and 4-fluorobenzaldehyde (0.904 g, 0.0072 mol) were added and the reaction mixture was heated to about 100 C for about 4 hours. After completion of reaction, water was added and extracted in ethyl acetate.
Organic layer was concentrated, purified by column using 7% ethyl acetate/hexane as eluent to obtain the title compound. (Yield: 0.6g) Mass-248 LCMS-M+1 (248.97) Step 2: Synthesis of 3-{(3S)-4-[(4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-y1]-3-1(S)-{4-[(4-chlorophenyl)sulfanyllphenyl}(hydroxy)methyll-4-oxobuty1}-1,2,3-benzotriazin-4(31/)-one To a solution of the 3- {4-[(45)-4-benzy1-2-oxo-1,3-thiazolidin-3-y]]-4-oxobuty11-1,2,3-benzotriazin-4(31/)-one (0.2 g, 0.00049 mol) in dichloromethane (5m1) under argon atmosphere cooled to about 0 C, titanium tetrachloride (0.12 g, 0.00063 mol) was added slowly. After about 30 minutes, tetramethylethylenediamine (0.068 g, 0.00058 mol) was added at about 0 C. The reaction mixture was stirred for about 45 minutes at the same temperature and then a solution of 4-[(4-chlorophenypsulfanyl]benzaldehyde (0.206 g, 0.00083 mol) in dichloromethane (5 ml) was added very slowly. This reaction mixture was again stirred for about 5 hours at room temperature. On completion, the reaction was quenched with ammonium chloride solution and subsequently by dilute hydrochloric acid and then extracted with dichloromethane and water, purified by column using 8%
ethyl acetate/hexane as eluent to obtain the title compound. (Yield: 0.150 g) Mass-657 LCMS-M+1 (658.02) Step 3: Synthesis of (2S)-2-[(5)-{4-[(4-chlorophenyl)sulfinyllphenyl}(hydroxy) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(41i)-yl)butanoic acid (Compound No. 1) To a solution of the 3-{(35)-4-[(45)-4-benzy1-2-oxo-1,3-thiazolidin-3-y1]-3-[(5)-{ 4- [(4-chlorophenyl)sulfanyl]phenyll (hydroxy)methy1]-4-oxobutyll -1,2,3 -benzotriazin-4(311)-one (0.1 g, 0.0001mol) in tetrahydrofuran (5m1) under argon atmosphere at 0 C, hydrogen peroxide solution (0.0102 g, 0.0003 mol) and then lithium hydroxide (0.006 g, 0.00015 mol) were added. The reaction mixture was stirred for about 2 hours at room temperature. The reaction was quenched by acidifying the reaction mixture with sodium bisulfate and extracting in ethyl acetate and water. Organic layer thus obtained was concentrated and purified by preparative TLC using 10%
methanol/dichloromethane as eluent to obtain the title compound. (Yield: 0.090 g) MS-497.95 LCMS-M-1 (496.04) NMR (DMSO-d6, 400 MHz) 8: 8.04-8.06 (2H, d, J= 8.0 Hz), 7.92-7.93 (1H, d, J =
4.0Hz), 7.81-7.83 (1H, d, J= 8.0 Hz), 7.67-7.69 (2H, d, J = 8.0 Hz), 7.57-7.59 (4H, d, J =
8 Hz), 7.42-7.44 (2H, d, J = 8 Hz), 4.84 (1H, m), 4.38-4.29 (2H, m), 2.54-2.57 (1H, m), 2.07 (1H, m), 1.89 (1H, m).
The following compounds were prepared by following above route of synthesis:
(25)-2- [(5)- { 4-[(3,4-difluorophenyOsulfinyl]phenyll(hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yDbutanoic acid (Compound No. 3);
Mass: 499.48 (2S)-2-[(5)- {4- [(2,3 -dichlorophenypsulfinyl]phenyll (hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 4);
Mass: 532.39 (2S)-2-[(5)- {4- [(2,4-dimethylphenypsulfinyl]phenyll(hydroxy)methyl] -4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 5);
Mass: 491.55 Step 4: Synthesis of (2S)-2- [(S)- (4-[(4-chlorophenyl)sulfonyllphenyl)(hydroxy) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(41i)-yl)butanoic acid (Compound No. 2) To a solution of (25)-2-[(5)-{4-[(4-chlorophenypsulfinyl]phenyll(hydroxy)methyl]
-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (0.09 g, 0.00018 mol) in chloroform (5m1) at about 0 C, metachloroperbenzoic acid (0.124 g, 0.00072 mol) was added and the reaction mixture was stirred for about 1 hour at room temperature. On completion, the reaction was quenched by sodium metabisulphite solution and then extracted in dichloromethane. The organic layer was dried with sodium sulphate and concentrated, purified by preparative TLC and eluted in 10% methanol/dichloromethane to obtain the title compound. (Yield: 0.04 g) MS-513.95 LCMS-M-1 (512.00) NMR(DMS0d6, 400 MHz) 6: 8.16 (2H, m), 8.08 (1H, m), 7.93-7.95 (4H, d, J = 8.0 Hz), 7.82-7.84 (1H, d, J= 8.0 Hz), 7.68-7.70 (2H, d, J = 8 Hz), 7.53-7.55 (2H, d, J
= 8 Hz), 4.90 (1H, m), 4.30-4.40 (2H, m), 2.50 (1H, m),1.90-2.10 (2H, m).

The following compounds can be prepared by following above route of synthesis:

(25)-2-[(5)-{4-[(4-Fluorophenypsulfonyl]phenyll(hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(41])-yl)butanoic acid (Compound No. 6) Mass: 497.49 (25)-2-[(5)-{4-[(3,4-Difluorophenyl)sulfonyl]phenyll(hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(41])-yl)butanoic acid (Compound No. 7) Mass: 515.48 2- [ {4- [(2,3 -Dichlorophenyl)sulfonyl]phenyll (hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 8) Mass: 548.39 (25)-2-[(5)-{4-[(2,4-Dimethylphenyl)sulfonyl]phenyll(hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 9) Mass: 507.55 Synthetic procedure for Scheme I (Path B) Exam ele II: S nthesis of 2S -2- S -H drox 4- 4-methox ohenox .hen meth 1 -4-(4-oxo-1,2,3-benzotriazin-441D-yl)butanoic acid (Compound No. 56) Step 1: Synthesis of 4-(4-methoxyphenoxy)benzaldehyde To a solution of 4-methoxy phenol (1.0 g, 0.0080 mol) in dimethylformamide (5m1), potassium carbonate (3.3 g, 0.024 mol) and 4-fluorobenzaldehyde (1.1 g, 0.0088 mol) were added and the reaction mixture was heated to about 100 C for about 4 hours.
On completion of reaction, water was added to it and extracted in ethyl acetate. The organic layer was concentrated, and purified by column using 7% ethyl acetate/hexane as eluent to obtain the title compound. (Yield: 0.9 g) Step 2: Synthesis of 3-[(3S)-4-[(4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-y1]-3-{(S)-hydroxy14-(4-methoxyphenoxy)phenyl]methy1}-4-oxobuty11-1,2,3-benzotriazin-4(3H)-one To a solution of 3-[4-((4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-y1)-4-oxobuty1]-benzo[d][1,2,3]triazin-4-one (5.5 g, 0.013 mol) in dichloromethane (50 ml) under argon atmosphere at 0 C, titanium tetrachloride (3.19 g, 0.0169 mol) was added slowly. The reaction mixture was stirred for about 30 minutes and then tetramethylethylenediamine (3.77 g, 0.0325 mol) at 0 C was added slowly and the reaction mixture continued to stir for about 45 minutes at the same temperature. Subsequently, a solution of 4-(4-methoxyphenoxy)benzaldehyde (5.2 g, 0.022 mol) in dichloromethane (20 ml) was added slowly and allowed to stir for about 5 hours. On completion, the reaction was quenched with ammonium chloride solution and subsequently by dilute hydrochloric acid, extracted with dichloromethane and water, and purified by column using 8% ethyl acetate/hexane to obtain the title compound. (Yield: 2.6 g) Step 3: Synthesis of (2S)-2-{(5)-hydroxy[4-(4-methoxyphenoxy)phenyllmethy1}-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 56) To a solution of the 3-[(35)-4-[(45)-4-benzyl-2-oxo-1,3-thiazolidin-3-y1]-3-{(5)-hydroxy[4-(4-methoxyphenoxy)phenyl]methy11-4-oxobutyl]-1,2,3-benzotriazin-4(3H)-one (2.6 g, 0.0040 mol) in tetrahydrofuran (30 ml) under argon atmosphere at about 0 C, hydrogen peroxide solution (0.408 g, 0.012 mol) and then lithium hydroxide (0.256 g, 0.0061 mol) were added and this reaction mixture was stirred for about 2 hours. The reaction was quenched by acidifying the reaction mixture with sodium bisulfate and extracting with ethyl acetate and water. The organic layer was concentrated, and purified by column using 8% methanol/dichloromethane as eluent to obtain the title compound.
(Yield: 0.9g) MS-461.46 LCMS-M-1 (460.08) NMR(DMSO-d6, 400 MHz) 6: 8.19-8.21 (1H, d, J= 8.0 Hz), 8.15-8.17 (1H, d, J=
8.0 Hz), 8.04-8.08 (1H, d, J= 16.0 Hz), 7.89-7.92 (1H, d, J= 12.0 Hz), 7.18-7.20 (2H, d, J=
8 Hz), 6.93 (4H, d), 6.72-6.74 (2H, d, J= 8 Hz), 4.77-4.78 (1H, m, J= 4 Hz), 4.30-4.40 (2H, m), 3.73 (3H, s), 2.59 (1H, m), 2.03-2.07 (2H, m).

The following compounds were prepared by following above route of synthesis:

(25)-2-[(5)-[4-(3-Chloro-4-fluorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(41/)-yl)butanoic acid (Compound No. 57) Mass: 482.28 (25)-2-[(5)-[4-(4-Chloro-3-methylphenoxy)pheny]](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yebutanoic acid (Compound No. 58) Mass: 478.25 (2S)-2-[(8)-[4-(4-Chloro-2-fluorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yObutanoic acid (Compound No. 59) Mass: 482.28 (25)-2-[(5)-[4-(4-Fluorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(414)-yebutanoic acid (Compound No. 60) Mass: 448.29 (25)-2- [(5)- [4-(3 ,4-Difluorophenoxy)phenyl ] (hydroxy)methyl] -4-(4-oxo-1,2,3 -benzotriazin-3(414)-yebutanoic acid (Compound No. 61) Mass: 466.31 (25)-2-[(5)-[4-(2-Chlorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(414)-yebutanoic acid(Compound No. 62) Mass: 464.26 (25)-2-[(5)-[4-(3-Chlorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 63) Mass: 464.26 (25)-2-[(5)-[4-(2,6-Difluorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 64) Mass: 466.31 (25)-2-[(5)-[4-(2,5-Dichlorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(414)-yObutanoic acid (Compound No. 65) Mass: 498.25 and 500.16 (25)-2-[(5)-[4-(2-Chloro-4-fluorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(41/)-yObutanoic acid (Compound No. 66) Mass: 482.28 (25)-2-1(5)-Hydroxy[4-(3-methoxyphenoxy)phenyl]methyll-4-(4-oxo-1,2,3-benzotriazin-3(414)-yebutanoic acid (Compound No. 67) Mass: 460.30 (25)-2-[(5)-[4-(2-Ch1oro-4-methoxyphenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yObutanoic acid (Compound No. 68) Mass: 494.29 (2S)-2-[(S)-[4-(2,4-Difluorophenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 69) Mass: 466.31 (25)-2-[(5)-[3-Fluoro-4-(4-methylphenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yebutanoic acid (Compound No. 70) Mass: 462.36 (25)-2-[(5)-[3-Fluoro-4-(3-methylphenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 71) Mass: 462.34 (2S)-2-[(5)-[4-(3,4-Dimethylphenoxy)-3-fluorophenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 72) Mass: 476.46 (25)-2-[(5)-[4-(3,4-Dichlorophenoxy)-3-fluorophenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 73) Mass: 516.33 and 518.29 (25)-2-[(5)-[4-(4-tert-Butylphenoxy)-3-fluorophenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 74) Mass: 504.44 (25)-2-[(5)-[3-Fluoro-4-(4-methoxyphenoxy)phenyl](hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 75) Mass: 478.38 Synthetic Procedure For Scheme II
Example III: Synthesis of 3-[(3S,4S)-4-(4-Aminopheny1)-3-{ [(4S)-4-benzy1-2-oxo-1,3-thiazo lidin-3 carbony11-4-hydroxybutyll -1,2,3 -benzotriazin-4131])-one Step 1: Synthesis of 34(3S)-41(4S)-4-benzy1-2-oxo-1, 3-thiazolidin-3-y1]-31(S)-hydroxy(4-nitrophenyl)methy1]-4-oxobuty1}-1,2,3-benzotriazin-4(311)-one To a solution of 3-{4-[(45)-4-benzy1-2-oxo-1,3-thiazolidin-3-y1]-4-oxobutyll-1,2,3-benzotriazin-4(3H)-one (20 g, 0.049 mol) in dichloromethane (350 ml) at about 0 C, titanium tetrachloride (58.8 ml, 0.311 mol) was added and the reaction mixture was stirred for about 20 minutes at room temperature (-25 C). To this, tetramethylethylenediamine (18.5 ml, 0.122 mol) was added at 0 C and the reaction mixture was allowed to stir for about 20 minutes. At the same temperature, 4-nitrobenzaldehyde (12.6 g, 0.083 mol) in dichloromethane (50 ml) was added and allowed to stir for about 2 hours at room temperature (-25 C). On completion, saturated solution of ammonium chloride and subsequently dilute hydrochloric acid were added to the reaction mixture.
Organic layer was extracted in dichloromethane, concentrated, purified on silica gel (60-120 mesh) using 25% ethyl acetate:hexane as eluent to get the desired product. (Yield: 18.2g) MS: 560.15 (M+1) Step 2: Synthesis of 3-[(3S,4S)-4-(4-aminopheny1)-3-{[(4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-yl]carbonyll-4-hydroxybutyll-1,2,3-benzotriazin-4(31/)-one To a solution of 3-1(35)-4-[(45)-4-benzy1-2-oxo-1,3-thiazolidin-3-y1]-3-[(5)-hydroxy(4-nitrophenyl)methyl]-4-oxobutyll-1,2,3-benzotriazin-4(3H)-one (18 g, 0.032 mol) in tetrahydrofuran (100 ml) and methanol (100 ml), 10% Pd/C (6.0 g) was added at room temperature (-25 C) and H2 was supplied in Parr apparatus at 50 psi for about one hour. The reaction mixture was filtered through celite and the residue was washed with 10% methanol/dichloromethane. The filtrate was concentrated, purified on silica gel (60-120 mesh) column using 60% ethyl acetate:hexane as eluent to get desired product. (Yield:
14.57 g) MS: 512.02 (M-18) Synthetic procedure for Scheme III

Example IV: Synthesis of (2S)-2-1(S)-14-(1[2-fluoro-44trifluoromethyl) phenyl]carbonyl}aminolphenyl](Ilydroxy)methyll-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 46) Step 1: Synthesis of N-14- [(1S,2S)-2-11(4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-yl]carbonyl}-1-hydroxy-4-(4-oxo-1,2,3-benzotriazin-3(41/)-Abutyliphenyll-2-fluoro-4-(trifluoromethyl)benzamide To a solution of 3-[(3S,45)-4-(4-aminopheny1)-3-1[(45)-4-benzy1-2-oxo-1,3-thiazolidin-3-yl]carbony1}-4-hydroxybuty1]-1,2,3-benzotriazin-4(3H)-one (0.3 g, 0.00057 mol) in dichloromethane (40 ml), triethylamine (0.24 ml, 0.0017 mol) was added at about 0 C. To this reaction mixture, 2-fluoro-4-trifluoromethyl benzoylchloride (0.19 g, 0.00086 mol) was added under nitrogen atmosphere and the reaction mixture was allowed to stir for about 2 hours at room temperature. On completion, water was added and the organic layer was extracted and concentrated to get crude product. (Yield: 153 mg) Step 2: Synthesis of (2S)-2-[(S)-[4-(112-fluoro-4-(trifluoromethyl)phenylicarbonyll amino)phenyll(hydroxy)methyll-4-(4-oxo-1,2,3-benzotriazin-3(41/)-Abutanoic acid (Compound No. 46) To the solution of N-14-[(1S,25)-2- {[(4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-yl] carbonyl} -1-hydroxy-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butyl]phenyll -2-fluoro-4-(trifluoromethyl) benzamide (0.153 g, 0.000213 mol) in tetrahydrofuran (20 ml), hydrogen peroxide (0.022 g, 0.00064 mol), lithium hydroxide (0.0134 g, 0.000032 mol) and water (2.0 ml) were added and the reaction mixture was stirred for about one hour at room temperature. The organic layer was extracted with ethyl acetate, dried over anhydrous sodium sulphate, and concentrated to get crude product. Purification was done on preperative TLC using 10% methanol:dichloromethane as eluent to get the title product.
(Yield: 61.0 mg) MS: 545.16 (M+1) NMR (DMSO-d6, 400 MHz), 6: 10.56 (1H, s), 8.22-8.17 (2H, m), 8.07 (1H, t, J =
7.44 Hz), 7.92-7.87 (3H, m), 7.73 (1H, d, J= 8.04Hz ), 7.56 (2H, d, J= 8.4 Hz), 7.25 (2H, d, J
= 8.4 Hz), 4.82 (1H, d, J= 6.04Hz), 4.40-4.32 (2H, m), 2.75-2.60 (1H, m), 2.30-2.0 (2H, m) Example V: Synthesis of (2S)-2-1(S)-(4-{ [(4-ethylphenyl)carbonyliaminolphenyl) (hydroxy)methy1J-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 10) Step 1: Synthesis of 3-{(3S)-4-1(4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-y11-3-[(S)-hydroxy(4-nitrophenyl)methy11-4-oxobuty1}-1,2,3-benzotriazin-4(31/)-one To a solution of 3- {4-[(4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-y1]-4-oxobutyll-1,2,3-benzotriazin-4(3H)-one (1 g, 0.0025 mol) in dichloromethane (20 ml) at 0 C, titanium tetrachloride (2.94 ml, 0.0029 mol) was added drop wise and the reaction mixture was stirred for about 40 minutes at room temperature (-25 C). To this, tetramethylethylenediamine (0.712 g, 0.0061 mol) was added at about 0 C and the reaction mixture was allowed to stir for another 30 minutes. At same temperature, a solution of 4-nitrobenzaldehyde (0.64 g, 0.0042 mol) in dichloromethane (50 ml) was added to the reaction mixture and allowed to stir for about 2 hours at room temperature (-25 C). On completion, saturated solution of ammonium chloride was added and the reaction mixture was worked up by dichloromethane and water. Purification was done on silica gel (60-120 mesh) using 30% ethyl acetate:hexane as eluent to get the title product.
(Yield: 0.62g) MS: 559.91 (M+1) Step 2: Synthesis of 3-1(3S,4S)-4-(4-aminopheny1)-3-11(4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-yllcarbonyll-4-hydroxybutyll-1,2,3-benzotriazin-4(31/)-one To a solution of 3-1(3S)-4-[(4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-y1]-3-[(S)-hydroxy(4-nitrophenypmethyl]-4-oxobuty1}-1,2,3-benzotriazin-4(311)-one (0.61 g, 0.0011 mol) in tetrahydrofuran (20 ml), 10% Pd/C (0.5 g) at room temperature (-25 C) was added and H2 was supplied using balloon for about 2 hours. The reaction mixture was filtered through celite and the residue was washed with 10% methanol:dichloromethane.
The filtrate was concentrated to get the desired compound. (Yield: 0.6g) MS: 511.94 (M-18) Step 3: Synthesis of N-14-[(1S,2S)-2-{[(45)-4-benzy1-2-oxo-1,3-thiazolidin-3-yl]carbony1}-1-hydroxy-4-(4-oxo-1,2,3-benzotriazin-3(41/)-y1)butyllpheny11-4-ethylbenzamide To a solution of 3-[(3S,4S)-4-(4-aminopheny1)-3-1[(4S)-4-benzy1-2-oxo-1,3-thiazolidin-3-yl]carbonyl} -4-hydroxybuty1]-1,2,3-benzotriazin-4(311)-one (0.6 g, 0.0011 mol) in dichloromethane (20 ml), triethylamine (0.47 ml, 0.0034 mol) was added at about 0 C. Afterwards, 4-ethyl benzoylchloride (0.29 g, 0.0017 mol) was added and the reaction mixture was stirred for about 30 minutes at 0 C. The reaction was worked up with dichloromethane and water to get crude product. (Yield: 680 mg) MS: 662.04 (M+1) Step 4: Synthesis of (2S)-2-[(S)-(4-{[(4-ethylphenyl)carbonyl]aminolphenyl)(hydroxy) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 10) To the solution of N-14-[(1S,29-2-1[(45)-4-benzyl-2-oxo-1,3-thiazolidin-3-yl]carbonyl} -1-hydroxy-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butyllphenyl} -4-ethylbenzamide (0.35 g, 0.00053 mol) in tetrahydrofuran (10 ml), hydrogen peroxide (0.3m1, 2.65 moles) was added and reaction mixture was stirred for about 15 minutes at 0 C. Subsequently, lithium hydroxide (0.033 g, 0.00079 mol) and water (5 ml) were added to it and again stirred for about 2 hours at room temperature. On completion, the reaction was quenched by adding water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, concentrated and purified by preparative TLC using 10% methanol:dichloromethane as eluent to get the title product.
(Yield: 84.0 mg) MS: 485.17 (M-1) NMR (DMSO-d6,400 MHz), 8: 10.06 (1H, s), 8.20-8.15 (2H, m), 8.06-8.02 (1H, m), 7.89-7.85 (3H, m), 7.61 (2H, d, J= 8.4 Hz), 7.35 (2H, d, J= 8.4 Hz), 7.21 (2H, d, J= 8.4 Hz), 4.80-4.78 (1H, m), 4.40-4.32 (2H, m), 2.70-2.65 (3H, m), 2.20-2.00 (2H, m).

The following compounds were prepared by following above route of synthesis:

(2S)-2-[(S)-(4-{ [(4-Chlorophenyl)carbonyl] amino phenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(41/)-yl)butanoic acid (Compound No. 11) Mass: 492.91 (2S)-2-[(S)-(4-{ [(3,4-Dichlorophenyl)carbonyl] amino phenyl)(hydroxy)methyl] -(4-oxo-1,2,3-benzotriazin-3(41/)-yl)butanoic acid (Compound No. 12) Mass: 528.84 (2S)-2-[(S)-Hydroxy(4-{ [(4-methoxyphenyl)carbonyl] amino phenyl)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(41/)-yObutanoic acid (Compound No. 13) Mass: 489.97 (2S)-2-[(S)-Hydroxy(4- [(3 -methoxyphenyl)carbonyl] amino } phenyl)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(41/)-yl)butanoic acid (Compound No. 14) Mass: 489.97 (2S)-2-[(S)-Hydroxy(4-{ [(4-methylphenyl)carbonyl]amino } phenyl)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(41-/)-yObutanoic acid (Compound No. 15) Mass: 473.01 (2S)-2-[(S)-(4- [(4-F luorophenyl)carbonyl] amino } phenyl)(hydroxy)methyl -4-(4-oxo-1,2,3-benzotriazin-3(41/)-yObutanoic acid (Compound No. 16) Mass: 477.96 (25)-2- {(S)-Hydroxy[4-({ [4-methoxy-3-(trifluoromethyl)phenyl ]carbonyl}
amino)phenyl] methy11-4-(4-oxo-1,2,3-benzotriazin-3(41/)-y1)butanoic acid (Compound No. 17) Mass: 557.94 (25)-2- [(S)-Hydroxy(4- [(5-methyl-1,2-oxazol-3 -yl)carbonyl] amino phenyl) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(41/)-yl)butanoic acid (Compound No. 18) Mass: 464.96 (25)-2- [(S)-(4- [(3 -Chloro-4-fluorophenyl)carbonyl] amino } phenyl)(hydroxy) methy1]-4-(4-oxo-1,2,3-benzotriazin-3(41/)-y1)butanoic acid (Compound no. 19) Mass: 510.80 (25)-2-[(S)-Hydroxy{4-[(phenylcarbonypamino]phenyllmethyl]-4-(4-oxo-1,2,3-benzotriazin-3(41/)-y1)butanoic acid (Compound No. 20) Mass: 459.95 (25)-2- [(S)-Hydroxy(4- [(4-propylphenyl)carbonyl] amino phenyl)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(41/)-yl)butanoic acid (Compound No. 21) Mass: 501.92 (25)-2-[(S)-Hydroxy{4-[(phenoxycarbonyl)amino]phenyllmethyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 22) Mass: 475.92 (2S)-2-[(S)-Hydroxy {4-[(phenylacetypamino]phenyllmethyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-y1)butanoic acid (Compound No. 23) Mass: 473.94 (25)-2- [(S)-(4- { [(2,4-D ichlorophenyl)carbonyl] amino phenyl)(hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-y1)butanoic acid (Compound No. 24) Mass: 526.84 (25)-2- [(S)-Hydroxy(4- [(2-methylphenyl)carbonyl]aminolphenypmethyl]-4-(4-oxo-1,2,3-benzotriazin-3(411)-y1)butanoic acid (Compound No. 25) Mass: 472.92 (25)-2- [(S)-(4- [(2-Fluorophenyl)carbonyl]aminolphenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yDbutanoic acid (Compound No. 26) Mass: 476.88 (25)-2- [(S)-(4- [(3 -Chlorophenyl)carbonyl] aminolphenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 27) Mass: 492.85 (25)-2- [(S)-Hydroxy(4- [(3-methylphenyl)carbonyl]aminolphenyl)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 28) Mass: 472.92 (25)-2- [(S)-(4- [(3-Fluorophenyl)carbonyl]aminolphenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(411)-y1)butanoic acid (Compound No. 29) Mass: 476.88 (25)-2-[(S)-(4- [(2,6-Dimethoxyphenyl)carbonyl]aminolphenyl)(hydroxy) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 30) Mass: 518.92 (25)-2- [(5)- {4-[(Cyclopentylcarbonyl)amino]phenyll(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 31) Mass: 450.94 (25)-2- [(5)-Hydroxy(4- [(2,4,5 -trifluoro-3 -methoxyphenyecarbonyl] amino}
phenyl)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 32) Mass: 543.09 (25)-2-[(5)-Hydroxy(4-{ [(2,3 ,4-trifluorophenyl)carbonyl] aminolphenyemethyl ] -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 33) Mass: 513.06 (25)-2- {(5)-Hydroxy[4-({ [2-(trifluoromethyl)pheny] ]carbonyl } amino)phenyl]

methyl} -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 34) Mass: 527.11 (25)-2- [(5)-(4- [(3,5 -D imethoxyphenyl)carbonyl] amino } phenyl)(hydroxy) methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yebutanoic acid (Compound No. 35) Mass: 519.13 (2S)-2-[(S)-(4- [(2,3 -Difluorophenypc arbonyl] amino }phenyl)(hydroxy)methyl ] -4-(4-oxo-1,2,3-benzotriazin-3(411)-yebutanoic acid (Compound No. 36) Mass: 495.04 (28)-2-[(S)-(4-{[(3,5-Dichlorophenyl)carbonyl]amino}phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 37) Mass: 526.99 (25)-2- [(5)-(4- [(2,4-Difluorophenyl)carbonyl] amino } phenyl)(hydroxy)methyl ] -4-(4-oxo-1,2,3-benzotriazin-3(411)-yebutanoic acid (Compound No. 38) Mass: 495.04 (25)-2- [(5)-(4- [(2,6-D ifluorophenyl)carbonyl] amino }
phenyl)(hydroxy)methyl ] -4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 39) Mass: 495.10 (25)-2-[(5)-Hydroxy(4- [(2-methoxyphenyl)carbonyl ] amino} phenyl)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 40) Mass: 489.16 (25)-2- [(S)- {4- [(Cyclohexylc arbonyl)amino] phenyl } (hydroxy)methy1]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 41) Mass: 465.20 (2S)-2-[(S)-(4- [(4-Ethoxyphenyl)carbonyl] amino }phenye(hydroxy)methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yObutanoic acid (Compound No. 42) Mass: 503.20 (2S)-2-[(S)-(4- [(3,4-Difluorophenyl)carbonyl ] amino } phenyl)(hydroxy)m ethyl] -4-(4-oxo-1,2,3-benzotriazin-3(411)-yebutanoic acid (Compound No. 43) Mass: 495.16 (25)-2- (5)-Hydroxy [4-( [4-(trifluoromethoxy)phenyl]carbonyllamino)phenyl]
methyl} -4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 44) Mass: 545.15 (25)-2- (5)-Hydroxy[4-({ [3-(trifluoromethyl)pheny] ] carbonyl} amino)phenyl]
methyl} -4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 45) Mass: 527.15 (2S)-2-[(S)-(4- [(3-Chloro-2,6-difluorophenyl)carbonyl ]aminolphenyl)(hydroxy) methy1]-4-(4-oxo-1,2,3-benzotriazin-3(411)-yObutanoic acid (Compound No. 47) Mass: 529.13 (25)-2- (5)-Hydroxy[4-({ [4-(trifluoromethyl)phenyl ] carbonyl} amino)phenyl]
methyl} -4-(4-oxo-1,2,3-benzotriazin-3(411)-yebutanoic acid (Compound No. 48) Mass: 527.16 (25)-2- [(5)-(4- [(2,5-Difluorophenyl)c arbonyl] amino }
phenyl)(hydroxy)methyl] -4-(4-oxo-1,2,3-benzotriazin-3(411)-yl)butanoic acid (Compound No. 49) Mass: 495.15 (25)-2- [(5)-(4- [(2,3-Difluoro-4-methylphenyl)carbonyl] amino) phenyl)(hydroxy) methy1]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 50) Mass: 509.18 (2S)-2-[(5)-[4-({ [4-Fluoro-3 -(trifluoromethyl)phenyl] carbonyl amino)phenyl]
(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(41/)-y1)butanoic acid (Compound No. 51) Mass: 545.15 (2S)-2- [(S)- {4-[(Cyclopropylcarbonyl)amino]phenyll(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 52) Mass: 423.19 (2S)-2-[(5)-(4- [(2-Ethylphenyl)carbonyllamino)phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(411)-yl)butanoic acid (Compound No. 53) Mass: 485.19 (25)-2-[(5) -Hydro xy(4- [(4-metho xyphenyl)acetyl] aminolphenyl)methyl] -4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 54) Mass: 503.20 (25)-2- [(5)- {4- [(Cyclobutylc arbonyl)amino]phenyll(hydroxy)methyl]-4-(4-o xo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 55) Mass: 437.21 Assay for Matrix Metalloproteinases (MMPs) New chemical entities of the present invention and corresponding standards used in the present invention were prepared (stock 10 mM) in 100% DMSO and subsequent dilutions were made in MMP assay buffer [50 mM HEPES, 10 mM CaC12, 150 nM
NaCl, 1 uM Zinc Acetate, 600 iM CHAPS (pH 7.4)]. Assays used human MMPs expressed either as full length or catalytic domain. The Collagenase (MMP-1), Gelatinase (MMP-9), Elastase (MMP-12) and membrane type-1 (MMP-14) were cleaved and activated using reagent APMA (4-amino phenyl mercuric acetate) to obtain active catalytic domains. In a typical 100 ul reaction assay mixture, 1.0 ul of desired MMP enzyme was incubated in buffered solution in absence or presence of 1.0 of NCEsistandards for 30 minutes.
Reaction was started with desired flurogenic substrate ¨ FAM-TAMRA (FAM-Thr-Pro-G1y-Pro-Leu-G1y-Leu-Dpa-A1a-Arg-Arg-Lys-TAMRA-NH2) at a final concentration of 10 uM per well and reaction was allowed to proceed for 45 minutes and rate of velocity was monitored (increase in RFUs) at excitation wavelength of 495 rim and emission 525 nm. Blank reaction rate (without enzyme) was subtracted from each value. The percent control was calculated using the following formula:

Percent activity = (inhibited rate/control rate) x 100.

IC50 values were calculated using least square regression analysis method by Graph-Pad prism version 4.2 software; using a 5-6 point dose response curve in presence of inhibitor. IC50 values were averaged for duplicate assay data and values tabulated.

The present invention relates to compounds that act as dual MMP-9/12 inhibitors, which have desirable activity profiles.

MMP-9 activities of the compounds disclosed in the invention, provided IC50 values from about 10 micromolar to about 1 nM, or from about 1 micromolar to about 1 nM, or from about 650 nM to about 1 nM, or from about 300 nM to about 1 nM, or from about 100 nM to about 1 nM, or from about 50 nM to about 1 nM, or from about 30 nM to about 1 nM, or from about 20 nM to about 1 nM, or from about 12 nM to about 1 nM, as compared to about 1.4 nM to 3.2 nM for marimastat.

MMP-12 activities of the compounds disclosed in the invention, provided IC50 values from about 10 micromolar to about 1 nM, or from about 1 micromolar to about 1 nM, or from about 300 nM to about 1 nM, or from about 100 nM to about 1 nM, or from about 50 nM to about 1 nM, or from about 30 nM to about 1 nM, or from about 20 nM to about 1 nM, or from about 15 nM to about 1 nM, or from about 7 nM to about 1 nM as compared to 0.2 nM to 0.9 nM for marimastat.

Claims (12)

1. A compound of Formula I:

including racemates, enantiomers and diastereomers thereof, or a pharmaceutically acceptable salt thereof, wherein, is phenyl, fluorophenyl, heteroaryl or heterocyclyl;
U is a bond, -NH-, -C(=O)- , -C(=S)-, -O-, -SO2_ or -S - wherein n is zero or an integer between 1 and 2;
V is a bond, -NH-, -C(=O)-, -C(=S)- or W is a bond, -NH-, -C(=O)- -C(=S)-, -O-, -S- or -SO2-;

is aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which can be further substituted by one or more substituent independently selected from R1 R1 is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C1-C6 alkyl, halogeno-C1-C6 alkoxy, azido, thiol, alkylthiol, -(CH2)n-OR f, -C(=O)-R f, -COOR f, --(CH2)n S(=O)m-NR f R q {wherein R f and R q are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and alkylheterocyclyl, n is as defined earlier and m is an integer 0-2};

is selected from heteroaryl or heterocyclyl.

(CH2)n NHC(=O)NR f R s, -(CH2)n-O-C(=O)- R f, -(CH2)n-NH-C(=O)-R f or
2. A compound according to claim 1, having the structure of Formula Ia including racemates, enantiomers and diastereomers thereof, or a pharmaceutically acceptable salt thereof wherein, is phenyl, fluorophenyl, heteroaryl or heterocyclyl;

Ll is a bond, -(CH2), -NHCO(CH2)6-, -(CH2)n C(=O)NH-, -NHC(=O)NH-, -SO2NH-, -NHSO2-, -SO2-, -NHC(=O)(O)-, -O-(CH2)n-(CH2)n-O-, -(CH2)n OC(=O)NH-, -C(=S)NH-, -NHC(=S)- or -NHC(=S)NH- wherein n is zero or an integer between 1 and 2;

is aryl, cycloalkyl, heteroaryl or heterocyclyl each of which can be further R1 is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C1-C6 alkyl, halogeno-C1-C6 alkoxy, azido, thiol, alkylthiol, -(CH2)n-OR f, -C(=O)-R f, -COOR f, -substituted by one or more substituents independently selected from R1;

NR f R q, -(CH2)n-CO)NR f R q, -(CH2)n-NHC(=O)-R f, -(CH2)n-O-C(=O)-NR f R q, (CH2)õ NHC(=O)NR f R q,, -(CH2)n-O-C(=O)- R f, -(CH2)n-NH-C(=O)-R f or alkyl, alkenyl, cycloalkyl aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and alkylheterocyclyl, n is as defined earlier and m is an integer 0-2};

is heteroaryl or heterocyclyl.

-(CH2)n S(=O)m-NR f R q {wherein R f and R q are independently selected from hydrogen,
3. A compound according to claim 1, having the structure of Formula Ib including racemates, enantiomers and diastereomers thereof, or a pharmaceutically acceptable salt thereof wherein, is mono, bi or polycyclic heteroaryl or heterocyclyl selected from the following:

v is zero or an integer between 1-4.

Ra is hydrogen or fluorine;

R1, L1and are as defined in claim 1.
4. A compound according to claim 1, having the structure of Formula Ic including racemates, enantiomers and diastereomers thereof, or a pharmaceutically acceptable salt thereof, wherein, L1a is S(O)n, NHCO(CH2)n and NHCO(O);

R a, are as defined in claim 1.
5. A compound of Formula I, which is:
(2S)-2-[(S)-{4-[(4-Chlorophenyl)sulfinyl]phenyl}(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 1);
(2S)-2-[(S)-{4-[(4-Chlorophenyl)sulfonyl]phenyl}(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 2);
(2S)-2-[(S)-{4-[(3,4-Difluorophenyl)sulfinyl]phenyl}(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 3);
(2S)-2-[(S)-{4-[(2,3-Dichlorophenyl)sulfinyl]phenyl}(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 4);
(2S)-2-[(S)-{4-[(2,4-Dimethylphenyl)sulfinyl]phenyl}(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 5);
(2S)-2-[(S)-{4-[(4-Fluorophenyl)sulfonyl]phenyl}(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 6);
(2S)-2-[(S)-{4-[(3,4-Difluorophenyl)sulfonyl]phenyl}(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 7);
2-[{4-[(2,3-Dichlorophenyl)sulfonyl]phenyl}(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 8);

(2S)-2-[(S)-{4-[(2,4-Dimethylphenyl)sulfonyl]phenyl}(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 9);
(2S)-2-[(S)-(4-{[(4-Ethylphenyl)carbonyl]amino}phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 10);
(2S)-2-[(S)-(4-{[(4-Chlorophenyl)carbonyl]amino}phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 11);
(2S)-2-[(S)-(4-{[(3,4-Dichlorophenyl)carbonyl]amino}phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 12);
(2S)-2-[(S)-Hydroxy(4-{[(4-methoxyphenyl)carbonyl]amino}phenyl)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 13);
(2S)-2- [(S)-Hydroxy(4-{[(3-methoxyphenyl)carbonyl]amino}phenyl)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 14);
(2S)-2-[(S)-Hydroxy(4-{[(4-methylphenyl)carbonyl]amino}phenyl)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 15);
(2S)-2-[(S)-(4-{[(4-Fluorophenyl)carbonyl]amino}phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 16);
(2S)-2- (S)-Hydroxy[4-({ [4-methoxy-3-(trifluoromethyl)phenyl]carbonyl}amino) phenyl]methyl}-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 17);
(2S)-2- [(S)-Hydroxy(4-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}phenyl) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 18);
(28)-2-[(S)-(4-{[(3-Chloro-4-fluorophenyl)carbonyl]amino}phenyl)(hydroxy) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 19);
(2S)-2-[(S)-Hydroxy{4-[(phenylcarbonyl)amino]phenyl}methyl]-4-(4-oxo-1,2,3-benzotriazin-3 (4H)-yl)butanoic acid (Compound No. 20);
(2S)-2-[(S)-Hydroxy(4-{[(4-propylphenyl)carbonyl]amino}phenyl)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 21);
(2S)-2-[(S)-Hydroxy{4-[(phenoxycarbonyl)amino]phenyl}methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 22);
(2S)-2-[(S)-Hydroxy{4-[(phenylacetyl)amino]phenyl}methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 23);
(2S)-2-[(S)-(4-{[(2,4-Dichlorophenyl)carbonyl]amino}phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 24);
(2S)-2-[(S)-Hydroxy(4-{[(2-methylphenyl)carbonyl]amino}phenyl)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 25);
(2S)-2- [(S)-(4-{[(2-Fluorophenyl)carbonyl]amino}phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 26);
(2S)-2-[(S)-(4-{[(3-Chlorophenyl)carbonyl]amino}phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 27);

(2S)-2- [(S)-Hydroxy(4-{[(3-methylphenyl)carbonyl]amino phenyl)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 28);
(2S)-2- [(S)-(4-{[(3-Fluorophenyl)carbonyl]amino} phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 29);
(2S)-2- [(S)-(4-[(2,6-Dimethoxyphenyl)carbonyl]aminolphenyl)(hydroxy) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 30);
(2S)-2-[(S)- {4-{[(Cyclopentylcarbonyl)amino]phenyl} (hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 31);
(2S)-2- [(S)-Hydroxy(4-{[(2,4,5-trifluoro-3-methoxyphenyl)c arbonyl]amino phenyl) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 32);
(2S)-2- [(S)-Hydroxy(4-{[(2,3,4-trifluorophenyl)carbonyl]amino} phenyl)methyl]-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 33);

(2S)-2- (S)-Hydroxy[4-( [2-(trifluoromethyl)phenyl]carbonyl} amino)phenyl ]methyl} -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No.
34);

(2S)-2- [(S)-(4-{[(3,5-Dimethoxyphenypc arbonyl]amino phenyl)(hydroxy)methyl ]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 35);
(2S)-2- [(S)-(4-{[(2,3-Difluorophenyl)carbonyl]amino} phenye(hydroxy)methyl ]-(4-oxo-1,2,3-benzotriazin-3(4H)-yebutanoic acid (Compound No. 36);
(2S)-2- [(S)-(4-{[(3,5-Dichlorophenyecarbonyl]amino} phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 37);
(2S)-2-[(S)-(4-{[(2,4-Difluorophenyl)c arbonyl]amino phenyl)(hydroxy)me thyl ]-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 38);
(2S)-2-[(S)-(4-{[(2,6-Difluorophenyl)carbonyl]aminolphenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 39);
(2S)-2- [(S)-Hydroxy(4-{[(2-methoxyphenyl)carbonyl ]amino} phenypmethyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 40);
(2S)-2- [(S)- {4- [(Cyclohexylc arbonyl)amino]phenyl} (hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 41);
(2S)-2- [(S)-(4-{[(4-Ethoxyphenyl)carbonyl]amino phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 42);
(2S)-2- [(S)-(4-{[(3,4-Difluorophenyl)carbonyl]amino} phenyl)(hydroxy)methyl ]-(4-oxo-1,2,3-benzotriazin-3(4H)-yebutanoic acid (Compound No. 43);
(2S)-2- (S)-Hydroxy[4-({ [4-(trifluoromethoxy)phenyl]carbonyl} amino)phenyl methyl} -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 44);
(2S)-2- (S)-Hydroxy [4-( [3-(trifluoromethyl)phenyl]carbonyl} amino)phenyl methyl} -4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 45);
(2S)-2- [(S)- [4-( [2-Fluoro-4-(trifluoromethyl)phenyl]carbonyl amino)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 46);

(2S)-2-[(S)-(4-[(3-Chloro-2,6-difluorophenyl)carbonyl] amino} phenyl)(hydroxy) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 47);
(25)-2-(S)-Hydroxy[4-({ [4-(trifluoromethyl)phenyl] carbonyl} amino)phenyl]
methyl}-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 48);
(2S)-2-[(S)-(4-[(2,5-Difluorophenyl)carbonyl] amino} phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 49);
(2S)-2-[(S)-(4-[(2,3-Difluoro-4-methylphenyl)carbonyl] amino} phenyl)(hydroxy) methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 50);
(2S)-2-[(5)-[4-({ [4-Fluoro-3-(trifluoromethyl)phenyl ] carbonyl}
amino)phenyl]
(hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 51);
(2S)-2-[(5)-{4-[(Cyclopropylcarbonyl)amino]phenyl} (hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoicacid (Compound No. 52);
(2S)-2-[(S)-(4-[(2-Ethylphenyl)carbonyl]amino} phenyl)(hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoicacid (Compound No. 53);
(2S)-2-[(S)-Hydroxy(4-[(4-methoxyphenyl)acetyl] amino} phenyl)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoicacid (Compound No. 54);
(2S)-2-[(5)-{4-[(Cyclobutylcarbonyl)amino] phenyl} (hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoicacid (Compound No. 55);
(2 S)-2-(S)-Hydroxy [4-(4-methoxyphenoxy)phenyl] methyl}-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 56);
(25)-2-[(5)-[4-(3-Chloro-4-fluorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoicacid (Compound No. 57);
(25)-2-[(5)-[4-(4-Chloro-3-methylphenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoicacid (Compound No. 58);
(25)-2-[(5)-[4-(4-Chloro-2-fluorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoicacid (Compound No. 59);
(25)-2-[(5)-[4-(4-Fluorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 60);
(25)-2-[(5)-[4-(3,4-Difluorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 61);
(25)-2-[(5)-[4-(2-Chlorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid(Compound No. 62);
(25)-2-[(5)-[4-(3-Chlorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 63);
(25)-2-[(5)-[4-(2,6-Difluorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 64);
(25)-2-[(5)-[4-(2,5-Dichlorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoicacid (Compound No. 65);

(2S)-2-[(S)-[4-(2-Chloro-4-fluorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 66);
(2S)-2-[(S)-Hydroxy[4-(3-methoxyphenoxy)phenyl]methyl}-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 67);
(2S)-2-[(S)-[4-(2-Chloro-4-methoxyphenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 68);
(2S)-2-[(S)-[4-(2,4-Difluorophenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)butanoic acid (Compound No. 69);
(2S)-2-[(S)-[3-Fluoro-4-(4-methylphenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 70);
(2S)-2-[(S)-[3-Fluoro-4-(3-methylphenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 71);
(2S)-2-[(S)-[4-(3,4-Dimethylphenoxy)-3-fluorophenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 72);
(2S)-2-[(S)-[4-(3,4-Dichlorophenoxy)-3-fluorophenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 73);
(2S)-2-[(S)-[4-(4-tert-Butylphenoxy)-3-fluorophenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 74);
(2S)-2-[(S)-[3-Fluoro-4-(4-methoxyphenoxy)phenyl](hydroxy)methyl]-4-(4-oxo-1,2,3-benzo triazin-3(4H)-yl)butanoic acid (Compound No. 75);
including racemates, enantiomers and diastereomers thereof, or a pharmaceutically acceptable salt.
6. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 5, together with a pharmaceutically acceptable carrier, excipient or diluent.
7. A compound according to any one of claims 1 to 5, for use in the treatment or prophylaxis of an animal or a human suffering from an inflammatory or allergic disease.
8. A compound according to claim 7, wherein the inflammatory disease or allergic disease is asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, dry eye, neointimal proliferation associated with restenosis and ischemic heart failure, stroke, renal disease or tumour metastasis.
9. A pharmaceutical composition according to claim 6, further comprising one or more additional active ingredients selected from:
(a) Anti-inflammatory agents, (i) such as nonsteroidal anti-inflammatory agents piroxicam, diclofenac, propionic acids, fenamates, pyrazolones, salicylates, phosphodiesterase inhibitors including PDE-4 inhibitors, p38 MAP
Kinase/Cathepsin inhibitors, CCR-3 antagonists, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists, Cell adhesion inhibitors (specially ICAM), adenosine 2a agonists, (ii) leukotrienes LTC4/LTD4/LTE4/LTB4-Inhibitors, 5-lipoxygenase inhibitors and PAF-receptor antagonists, (iii) Cox-2 inhibitors (iv) other MMP inhibitors, (v) interleukin-I inhibitors, (vi) corticosteroids such as alclometasone, amcinonide, amelometasone, beclometasone, betamethasone, budesonide, ciclesonide, clobetasol, cloticasone, cyclomethasone, deflazacort, deprodone, dexbudesonide, diflorasone, difluprednate, fluticasone, flunisolide, halometasone, haloperedone, hydrocortisone, methylprednisolone, mometasone, prednicarbate, prednisolone, rimexolone, tixocortol, triamcinolone, ulobetasol, rofleponide, GW 215864, KSR 592, ST-126, dexamethasone and pharmaceutically acceptable salts, solvates thereof.
Preferred corticosteroids include, for example, flunisolide, beclomethasone, triamcinolone, budesonide, fluticasone, mometasone, ciclesonide, and dexamethasone;
(b) beta-agonists, suitable .beta.2-agonists include, for example, one or more of albuterol, salbutamol, biltolterol, pirbuterol, levosalbutamol, tulobuterol, terbutaline, bambuterol, metaproterenol, fenoterol, salmeterol, carmoterol, arformoterol, formoterol, and their pharmaceutically acceptable salts or (c) antihypertensive agents, (i) ACE inhibitors, e.g., enalapril, lisinopril, valsartan, telmisartan and quinapril, (ii) angiotensin II receptor antagonists and agonists, e.g., losartan, candesartan, irbesartan, valsartan, and eprosartan, (iii) .beta.-blockers, and (iv) calcium channel blockers;
solvates thereofone or more .beta.2- agonists;

(d) immunosuppressive agents, - cyclosporine, azathioprine and methotrexate, anti-inflammatory corticosteroids; and (e) anti-infective agents.
10. A process for preparing a compound of Formula VIII (Formula I when Ring A
is phenyl, U is -SO2-, V and W are bonds) and Formula lX (Formula I when Ring A
is phenyl, U is -O-, V and W are bonds) comprising:
a) reacting compound of Formula II

with a compound of Formula III

to give a compound of Formula IV

b) reacting a compound of Formula IV with a compound of Formula V, to give a compound of Formula VI, c) hydrolysing a compound of Formula VI (when X is S) to give a compound of Formula VII

d) oxidizing a compound of Formula VII to give a compound of Formula VIII
or e) hydrolysing a compound of Formula VI (when X is O) to give a compound of Formula IX
wherein, is aryl, cycloalkyl, heteroaryl or heterocyclyl each of which can be further substituted by one or more substituent independently selected from R1.
R1 is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C1-C6 alkyl, halogeno-C1-C6 alkoxy, azido, thiol, alkylthiol, -(CH2)n-OR f, -C(-O)-R f, -COOR f, -NR f R q, -(CH2)q-C(=O)NR f R q, -(CH2)q-NHC(=O)-R f, -(CH2)q-O-C(=O)-NR f R q, (CH12)n NHC(=O)NR f R q, -(CH2)n-O-C(=O)- R f, -(CH2)n-NH-C(=O)-R f or -(CH2)n S(=O)m-NR f R q {wherein R f and R q are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and alkylheterocyclyl, n is as defined earlier and m is an integer 0-2};

is selected from heteroaryl or heterocyclyl;

X is O or S ;

R k is H, halo, alkyl, alkoxy, cyano, halogeno-C1-C6 alkyl or halogeno-C1-C6 alkoxy;

z is 0-4;

Rx is alkyl, aryl or aralkyl.

L and W are O or S respectively; and
11. A process for preparing a compound of Formula XV (Formula I when Ring A is phenyl, U is -NH-, V is -CO- and W is -NH-) and XVIII (Formula I when Ring A
is phenyl, U is -NH-, V and W combined together are Rj) comprising a) Aldol addition of a compound of Formula X with a compound of Formula V

to give a compound of Formula XI

b) reducing a compound of Formula XI to give a compound of Formula XII

c) coupling a compound of Formula XII (when G1 is amino) with a compound of Formula XIII

to give a compound of Formula XIV

d) hydrolyzing a compound of Formula XIV to give a compound of Formula XV

or e) coupling a compound of Formula XII with a compound of Formula XVI
to give a compound of Formula XVII, f) hydrolyzing a compound of Formula XVII to give a compound of Formula XVIII
wherein, is aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which can be further substituted by one or more substituents independently selected from R1;
R1 is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C1-C6 alkyl, halogeno-C1-C6 alkoxy, azido, thiol, alkylthiol, -(CH2)n-OR f -C(=O)-R f, -COOR f, NR f R q, -(CH2)n-C(=O)NR f R q, -(CH2)n-NHC(=O)-R f, -(CH2)n- O-C(=O)-NR f R q, (CH2)n NHC(=O)NR f R q,, -(CH2)n-O-C(=O)- R f, -(CH2)n-NH-C(=O)-R f or -(CH2),S(=O)m-NR f R q {wherein R f and R q are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and alkylheterocyclyl, n is as defined earlier and m is an integer 0-2};

is selected from heteroaryl or heterocyclyl;
Rk is H, halo, alkyl, alkoxy, cyano, halogeno-C1-C6 alkyl or halogeno-C1-C6 alkoxy;

z is 0-4;

L and W are O or S respectively;
Rx is alkyl, aryl or aralkyl;

G is nitro or C(O)O-benzyl;

G1 is amino or COOH;

X is a leaving group for example halogen; and R j is -(CH2)0-1-CO-, -C(O)O-, -SO2-.
12. A process for preparing a compound of Formula XXI (Formula I when Ring A
is phenyl, U is -CO-V is-NH-, and W is a bond) Comprising:

a) coupling a compound of Formula XII (when G1 is COOH) Formula XII (when G1 is COOH) with a compound of Formula XIX

to give a compound of Formula XX

b) hydrolyzing a compound of Formula XX to give a compound of Formula XXI, wherein, is aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which can be further substituted by one or more substituent independently selected from R1 is alkyl, alkenyl, alkynyl, cyano, nitro, halogen, halogeno-C1-C6 alkyl, halogeno-C1-C6 alkoxy, azido, thiol, alkylthiol, -(CH2)n-OR f, -C(=O)-R f, -COOR f, -NR f R q, -(CH2)n-C(=O)NR f R q, -(CH2)n-NHC(=O)-R f, -(CH2)n-O-C(=O)-NR f R q, (CH2)n NHC(=O)NR f R q,, -(CH2)-O-C(=O)- R f, -(CH2)n -NH-C(=O)-R f or -(CH2)n S(=O)m-NR f R q {wherein R f and R q are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl aryl, heteroaryl, heterocyclyl, alkylaryl, alkylheteroaryl and alkylheterocyclyl, n is as defined earlier and m is an integer 0-2};

is selected from heteroaryl or heterocyclyl;
Rk is H, halo, alkyl, alkoxy, cyano, halogeno-C1-C6 alkyl or halogeno-C1-C6 alkoxy;
z is 0-4;

Rx is alkyl, aryl or aralkyl.

L and W are O or S respectively;
CA2807097A 2010-07-30 2011-07-14 Matrix metalloproteinase inhibitors Abandoned CA2807097A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1810/DEL/2010 2010-07-30
IN1810DE2010 2010-07-30
PCT/IB2011/053155 WO2012014114A1 (en) 2010-07-30 2011-07-14 Matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
CA2807097A1 true CA2807097A1 (en) 2012-02-02

Family

ID=44720049

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2807097A Abandoned CA2807097A1 (en) 2010-07-30 2011-07-14 Matrix metalloproteinase inhibitors

Country Status (11)

Country Link
EP (1) EP2598493A1 (en)
JP (1) JP2013537533A (en)
KR (1) KR20130042590A (en)
CN (1) CN103119030A (en)
AU (1) AU2011284397A1 (en)
BR (1) BR112013002370A2 (en)
CA (1) CA2807097A1 (en)
CO (1) CO6680674A2 (en)
MX (1) MX2013001240A (en)
SG (1) SG187654A1 (en)
WO (1) WO2012014114A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4008355A1 (en) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP3808339A1 (en) 2012-05-03 2021-04-21 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
JP6669499B2 (en) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド Therapeutic compounds
EP2958895B1 (en) 2013-02-20 2020-08-19 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN103304634B (en) * 2013-05-30 2015-04-29 温州芳植生物科技有限公司 Matrix metalloproteinase-2 polypeptide inhibitor and application
CN103254290B (en) * 2013-05-30 2014-09-03 南通广泰生化制品有限公司 Matrix metal proteinase-2 polypeptide inhibitors and application thereof
MX355330B (en) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS and USES THEREOF.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015150364A1 (en) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Substituted benzotriazinone butane acids and use thereof
CN106661008A (en) 2014-04-03 2017-05-10 拜耳制药股份公司 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
WO2015150362A2 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
WO2015150366A1 (en) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Cyclically substituted phenol ether derivatives and use thereof
WO2015150363A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof
US20170121315A1 (en) * 2014-06-12 2017-05-04 Bayer Pharma Aktiengesellschaft Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
MX2019002629A (en) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof.
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3937838A (en) 1966-10-19 1976-02-10 Aktiebolaget Draco Orally active bronchospasmolytic compounds and their preparation
US3700681A (en) 1971-02-16 1972-10-24 Pfizer 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4011258A (en) 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
ATE7689T1 (en) 1980-07-09 1984-06-15 Aktiebolaget Draco 1-(DIHYDROXYPHENYL)-2-AMINO-AETHANOL DERIVATIVES, PROCESSES AND MEANS FOR THEIR PREPARATION, AND AGENTS CONTAINING THESE DERIVATIVES.
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
CA1240708A (en) 1983-11-15 1988-08-16 Johannes K. Minderhoud Process for the preparation of hydrocarbons
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
JP2003528082A (en) 2000-03-21 2003-09-24 ザ プロクター アンド ギャンブル カンパニー Difluorobutyric acid metalloprotease inhibitor
MXPA03006876A (en) 2001-01-30 2003-11-13 Pfizer Prod Inc Processes for preparing chromanylbenzoic acids.
US6794510B2 (en) 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
GB0312654D0 (en) 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
PT1856063E (en) 2005-02-22 2012-04-12 Ranbaxy Lab Ltd 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
RS52575B (en) 2006-08-22 2013-04-30 Ranbaxy Laboratories Limited Process for preparing matrix metalloproteinase inhibitors and chiral auxiliary therefor

Also Published As

Publication number Publication date
KR20130042590A (en) 2013-04-26
JP2013537533A (en) 2013-10-03
BR112013002370A2 (en) 2017-06-20
WO2012014114A1 (en) 2012-02-02
SG187654A1 (en) 2013-03-28
MX2013001240A (en) 2013-08-27
CO6680674A2 (en) 2013-05-31
AU2011284397A1 (en) 2013-02-21
CN103119030A (en) 2013-05-22
EP2598493A1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
CA2807097A1 (en) Matrix metalloproteinase inhibitors
CA2812319A1 (en) Matrix metalloproteinase inhibitors
JP6002785B2 (en) Benzimidazole and imidazopyridine derivatives as sodium channel modulators
JP4592077B2 (en) 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1 (NK-1) antagonists for the treatment of vomiting, depression, anxiety and cough
CZ173398A3 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing thereof, process and intermediates for their preparation
AU2017200338A1 (en) (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
US11851428B2 (en) Activator of TREK (TWIK RElated K+channels) channels
CA2812361A1 (en) Matrix metalloproteinase inhibitors
CA2812362A1 (en) Matrix metalloproteinase inhibitors
US20080194565A1 (en) 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases
JP7338711B2 (en) DP antagonist
AU2018289731A1 (en) Amide derivatives as Nav1.7 and Nav1.8 blockers
JP2011518144A (en) 4-Benzylidene-3-methylpiperidine arylcarboxamide compounds useful as FAAH inhibitors
SK5082002A3 (en) Beta disubstituted metalloprotease inhibitors
RU2737433C2 (en) Benzo-n-hydroxyamide compounds having anti-tumor activity
US9193699B2 (en) Apoptosis inducing compounds
JPWO2017183723A1 (en) KCNQ2-5 channel activator
RAUF et al. International Bureau
JP2022551470A (en) Prostaglandin EP4 receptor antagonist compounds
NZ623090B2 (en) (4-phenylimidazol-2-yl)ethylamine derivatives useful as sodium channel modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130130

FZDE Discontinued

Effective date: 20140715